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Human papillomaviruses are small DNA viruses that have been identified as 
etiological agents for the induction of cancer in humans. Papillomavirus extra-
chromosomal genome or integrated subgenomic fragments have been found in 
cervical, vaginal, vulvar and anal carcinoma biopsies and also in head, neck and 
throat cancer tissues. HPV types that infect mucosal tissue are classified into 
high- and low-risk groups depending on the ability to progress from benign 
lesions to malignant neoplasias. Infection by low-risk HPV types is frequently 
asymptomatic or causes the formation of benign tumors, such as warts or 
condylomas. In most cases, the virus infection is eventually taken care of by the 
immune system. In rare cases, a persistent HPV infection is established, in 
which case immune responses are altered by the virus oncoproteins, and the 
immune system is not sufficient to remove either the virus or HPV-infected 
cells. This type of infection is established by HPV types that belong to the 
group of high-risk HPVs (HPV16, 18, 31, 33, 45, 52, etc.).  
Papillomaviruses are masters at hijacking host cell replication machinery as 
well as cellular DNA damage response pathways to amplify viral genomes. The 
co-localization of homologous recombination as well as non-homologous-end-
joining effector molecules to HPV DNA repair/recombination centers indicates 
the important role of cellular DNA damage response pathways in repairing the 
double-stranded DNA breaks that occur during viral DNA replication. The un-
licensed replication mode characteristic of HPVs often causes the collision of 
replication forks. Unfinished DNA replication products are then recognized by 
cellular DNA damage response pathways and subjected to DNA repair. While 
most double-stranded breaks are repaired properly, the generation of larger than 
unit-sized HPV molecules (oligomers) as well as integration into host cell 
genomic material may be the result of failed attempts to repair DNA damage.  
Integration of HR-HPV sequences into host cell genomic material is 
believed to be one of the critical events in the formation of cancer cell. Usually, 
HPVs integrate such that the regulatory role of the viral E2 protein to the viral 
oncogenes E6 and E7 is disrupted, allowing the E6 and E7 proteins to take con-
trol of regulating cellular growth by inhibiting cellular p53 and pRB family 
proteins. In addition, integration of HPV sequences into cellular DNA may dis-
rupt genes that are responsible for the control of cell growth, thereby releasing 
the inhibitory role of the gene products, which can subsequently lead to the 
uncontrolled growth of a cell. The co-occurrence of episomal and integrated 
forms of HPV genomes has also been detected in cancer tissues. In these cases, 
the expression of replication proteins from episomal molecules may initiate 
DNA replication from an integrated HPV origin of replication, thereby ampli-
fying both the integrated HPV sequences as well as the flanking cellular 
sequences. Depending on the location of the integration site, the amplification 
of cellular sequences may contribute to genomic instability. If the integration 
occurred in close proximity to a cellular oncogene, amplification of this 
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sequence may lead to the overexpression of the oncoprotein, which can again 
result in the uncontrolled growth of the cell.  
Papillomaviruses have been studied for decades after Harald zur Hausen 
proposed that HPV infection may be the cause of cervical cancer. PVs are quite 
species- and tissue-specific, and the first objective of PV research was to find a 
suitable in vitro system through which different functions of the viral life cycle 
could be analyzed. A breakthrough was achieved when it was discovered that 
bovine papillomavirus type 1 (BPV1) genes can be expressed and genomes can 
be replicated in the mouse fibroblast cell line C127. Our research group has also 
been involved in studying the mechanisms of DNA replication of the BPV1 
genome, and the results have been widely recognized and considered a major 
contribution to the field (Männik et al., 2002; Piirsoo et al., 1996; Ustav and 
Stenlund, 1991; Ustav et al., 1993). Since the organization of papillomavirus 
genomes is quite conserved, the information gained from BPV-1 studies, such 
as insights into the basic mechanisms of viral gene expression, DNA replication 
and the regulation thereof, can be extrapolated with caution to the majority of 
papillomaviruses. The study of human papillomaviruses took off when cell lines 
that stably maintain the PV genome as an extrachromosomal molecule were 
derived from patients infected with high-risk HPV types (W12-E, CIN612-9E). 
Furthermore, various immortalized epithelial cell lines have been isolated that 
support the replication of transfected HPV genomes. Despite these advances, 
the need for a more robust system to study papillomaviruses and to screen 
potential anti-HPV drugs encouraged us to continue searching for a cell line that 
is easy to culture and supports HPV genome replication. After HPV genomes 
were introduced into the human osteosarcoma cell line U2OS, the results of 
gene expression and DNA replication were compared to analogous studies 
made in keratinocytes. Surprisingly, we found that gene expression, episomal 
DNA replication and maintenance in U2Os cells are essentially the same as in 
keratinocytes. This encouraged us to further explore the use of this cell line for 
HPV studies. We discovered that U2OS cells are suitable to monitor HPV tran-
sient DNA replication, active mRNA transcription and translation into func-
tional proteins. Since no therapeutic drugs against HPV infection have been 
marketed, we believe that U2OS cells may have a promising future in screening 













2. LITERATURE REVIEW 
2.1 Papillomaviruses 
Papillomaviruses are small, non-enveloped, species-specific, epitheliotropic, 
double-stranded DNA (dsDNA) viruses that belong to the family Papillo-
maviridae. In addition to humans, they infect other mammals (such as rabbits, 
rodents, bovines, horses, etc.), birds and reptiles. According to the diversity of 
the nucleotide sequence of the major capsid protein L1, more than 200 types of 
human papillomaviruses (HPV) have been classified into 5 genera: Alpha-, 
Beta-, Gamma-, Mu- and Nupapillomaviruses (α, β, γ, μ, and ν), which infect 
different regions of epithelial tissue (Bernard et al., 2010; Bzhalava et al., 2015; 
de Villiers et al., 2004).  
HPVs infect the basal layer of epithelial tissue through microabrasion, and 
the infection is usually asymptomatic, but in some cases causes epithelial 
lesions (papillomas) such as warts on skin (β-HPVs) and condylomas on 
mucosa (α-HPVs). A variety of the HPVs that infect cutaneous tissue, such as 
HPV1 and HPV2, are often found in healthy skin samples and are therefore 
considered as a part of the normal microbiota of human skin. Under appropriate 
conditions, they may develop into a variety of clinically insignificant benign 
epithelial growths, such as warts or papillomas. However, certain other β-HPVs, 
such as HPV5 and HPV8, have been linked to non-melanoma skin cancer in 
immunocompromised and immunosuppressed patients with the rare hereditary 
disease Epidermodysplasia Verruciformis (EV) (Accardi and Gheit, 2014). 
HPV types infecting mucosal tissue (α-HPVs) are divided into high- and low-
risk groups according to their ability to cause lesions that can progress into 
malignant neoplasias. Low-risk HPV infections cause discomfort, but overall 
the disease is not life threatening, and the infection will be eliminated by the 
immune system. By contrast, the 19 types that are classified as high-risk 
(HPV16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73 and 82) 
(Gheit and Tommasino, 2011) can establish persistent infections and have been 
closely linked to the development of cervical cancer, with HPV16 being the 
predominant high-risk type worldwide. In addition to cervical cancer, HPV16 
and HPV18 have also been found in 70% of analyzed vaginal, 40% of vulvar, 
and 84% of anal carcinoma biopsies, as well as in head, neck, and throat cancer 
cells (De Vuyst et al., 2009).  
Progression from a premalignant lesion to invasive cancer usually takes 
years to occur, indicating that cancer development is a multistep process. Alt-
hough preventative cervical screening methods like Pap smear have been devel-
oped to detect potential pre-cancerous or cancerous cells in the cervix, HPV 
infection is not usually detected early enough to intervene at the right time. 
Therefore, cervical cancer is a serious health problem, especially in developing 
countries. It is also the second most common cause of cancer-related mortality 
in women worldwide. Currently, no therapeutic drugs have been marketed to 
cure HPV infection, and the vaccines that have been developed against nine 
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different HPV types have various limitations. Gardasil was the first preventative 
vaccine developed; it offers protection against four HPV types (HPV6, HPV11, 
HPV16, and HPV18) with partial cross-protection against HPV31 and HPV45 
and was approved by the Food and Drug Administration (FDA) in 2006 (De 
Vincenzo et al., 2013; Markowitz et al., 2007). Cervarix, licensed in 2007, was 
the second vaccine developed and is a bivalent vaccine that provides protection 
against high-risk HPV16 and HPV18 (Harper et al., 2004). The third vaccine, 
Gardasil 9, was approved by the FDA in 2014 and protects against 9 HPV 
types: HPV6, HPV11, HPV16, and HPV18 which were also the targets to the 
first generation of Gardasil, plus HPV31, HPV33, HPV45, HPV52, and HPV58, 
which are responsible for the remaining 20% of cervical cancers. To date, HPV 
vaccines have been marketed in more than 100 countries. However, not all of 
the countries have included the vaccines in national vaccination programs. As 
vaccination is quite expensive, this often prevents widespread use of the vac-
cines. Vaccination is recommended for girls at a young age, before the onset of 
sexual activity. Women up to 45 years of age may benefit from vaccination, but 
the overall effectiveness is quite low, as the vaccines only help women who 
have not already been infected with HPV prior to vaccination. For this reason, 
the FDA has not approved administration of the vaccine to all women up to age 45.  
 
 
2.2 Papillomavirus genome organization and viral proteins 
Papillomaviruses have circular double-stranded DNA genomes approximately  
8 kbp in length that typically contain 9 to 10 open reading frames (ORFs). The 
8 ORFs located in the early region of the viral genome encode non-structural 
proteins, and the two ORFs located in the late region encode structural proteins 
(Fig. 1). The viral genome also contains a non-coding upstream regulatory 
region (URR) that is about 1 kbp in size and contains cis elements for DNA 
replication initiation and gene transcription. 
The E1 protein is an ATP-dependent DNA helicase that binds to the E1 
binding site (E1BS) in the URR region and is responsible for melting DNA (at 
viral origin) and unwinding the double helix during replication fork progression 
(Sedman and Stenlund, 1998; Seo et al., 1993; Yang et al., 1993). The E1 and 
E2 proteins are two viral factors needed for DNA replication. They are also 
responsible for recruiting cellular replication factors to replicate viral DNA 
(Chiang et al., 1992; Ustav and Stenlund, 1991; Wilson et al., 2002; Yang et al., 
1993). The E1 protein can be divided into three functional regions. The  
C-terminal half of the protein carries an ATPase/helicase domain that can self-
assemble into hexamers and interact with the E2 protein and with the cellular 
polymerase α-primase and topoisomerase I (Clower et al., 2006; Masterson et 
al., 1998; Sun et al., 1998; Titolo et al., 1999). The origin-binding domain is 
located in the hinge region of E1 and is required for dimerization and binding to 
the viral origin (Titolo et al., 2003). The N-terminal half of E1 has a regulatory 
role and is required for efficient viral DNA replication in vivo but can be dis-
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pensable in vitro, as the C-terminal half of the protein together with the origin 
binding domain is sufficient to catalyze viral DNA replication (Amin et al., 
2000). The N-terminal part of E1 also includes cis elements that regulate the 
nucleocytoplasmic shuttling of E1 in vivo; such as a bipartite nuclear localiza-
tion signal (NLS), a Crm1-dependent nuclear export signal (NES), a cyclin  
E/A-binding motif (CBM), and specific Cdk2 phosphorylation sites (S92 and 
S106 in HPV31 and S89, S93, and S107 in HPV11) (Deng et al., 2004; Fradet- 
Turcotte et al., 2010; Ma et al., 1999; Yu et al., 2007). 
 
 
Figure 1. Schematic presentation of HPV11 genome. Genes from the early coding 
region are marked with blue arrows, genes from the late coding region are marked with 




E2 is a multi-functional protein that has important roles in transcription reg-
ulation, in the initiation of viral DNA replication, in genome segregation during 
mitosis, and in nuclear retention. Depending on its concentration and configu-
ration, E2 can act as either a transcription activator or a repressor. Full-length 
E2 protein at moderate concentrations acts as a transcription activator, but at 
higher concentrations, it acts as a transcription repressor (Abroi et al., 1996). 
Truncated E2, called E2C (also E8^E2), lacks a transactivation domain and is a 
replication and transcription repressor (Chiang et al., 1991; Lim et al., 1998; 
McBride et al., 1991). However, the heterodimer composed of both the full-
length and truncated forms of E2 is a replication activator, meaning that a single 
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transactivation domain is enough to activate replication and transcription (Kurg 
et al., 2006). The E2 protein is also a specificity factor for E1 during the initia-
tion of DNA replication, as it helps E1 specifically recognize the E1BS in the 
URR region by simultaneous binding of E2 protein with E1 and the E2 binding 
site (E2BS) in the URR region (Bonne-Andréa et al., 1997; Sedman and Sten-
lund, 1995; Ustav and Stenlund, 1991; Yang et al., 1991). In bovine papilloma-
virus type 1 (BPV1) and HPV18, it has been shown that E2 is also responsible 
for segregation of the viral genome between daughter cells through simultane-
ous binding with E2BSs in the PV genome and with host cell mitotic chromatin 
during cell division (Piirsoo et al., 1996; Ustav et al., 2015). 
The functions of the E4 protein are associated with the vegetative phase of 
infection, and this protein is highly expressed in the parabasal layer of infected 
tissue. E4 contributes to genome amplification and regulation of the viral life 
cycle, as it suppresses cell growth and arrests cell cycle progression at the G2/M 
phase (Doorbar, 2013; Nakahara et al., 2002). Also, in the presence of the 
E1^E4 fusion protein, the cellular cytokeratin matrix collapses, whereas nuclear 
lamins, tubulin and actin networks remain unaffected (Doorbar et al., 1991).  
The E5 protein is a transmembrane protein that interacts with growth factor 
receptors in the cell surface and stimulates cell growth (DiMaio and Mattoon, 
2001). E5 also contributes to host cell transformation and immune evasion by 
down-regulating the expression of cellular proteins involved in antigen presen-
tation at the cell surface (Ashrafi et al., 2002, 2005, 2006; Campo et al., 2010). 
According to sequence analysis, not all HPVs encode the E5 protein and some 
HPVs encode two E5 proteins (e.g., HPV11, Fig. 1).  
E6 is viral oncoprotein that prevents cell cycle blockage and apoptosis by 
inhibiting the activity of the tumor suppressor protein p53 (Scheffner et al., 
1990). 
E7 is also an oncoprotein and is responsible for driving the host cell into  
S-phase through the degradation of pRB family proteins (Boyer et al., 1996).  
The L1 protein is the major capsid protein expressed during the vegetative 
phase of infection in terminally differentiated epithelial cells. The coding 
sequence of the L1 gene is considered as the most conserved region within pap-
illomavirus genome, and therefore, PV classification relies on differences of 
this gene (de Villiers et al., 2004). 
L2 is minor capsid protein that is also expressed during the vegetative phase 
of infection in terminally differentiated epithelial cells. 
 
 
2.3 The HPV gene transcription 
Identification and accurate mapping of each mRNA produced by HPV is crucial 
for understanding the roles of viral gene products during DNA replication and 
RNA transcription, as well as how the expression of these gene products are 
regulated. Full transcription maps of various HPV types have been collected in 
the PaVE database (http://pave.niaid.nih.gov/), and transcription maps for 
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HPV5 and HPV18 in the U2OS cell-line are also available (Sankovski et al., 
2014; Toots et al., 2014). 
Depending on the type of HPV, the HPV genome consists of either 9 to 10 
ORFs. For initiation of mRNA synthesis, there are three conserved differentia-
tion-specific promoter regions at the end of the URR region and within the E6 
and E7 ORFs. For the addition of poly-A tails to the end of mature messenger 
RNAs, HPV genomes utilize two (early and late) polyadenylation cleavage 
sites. The early promoter (P90 for HPV11, P102 for HPV18, P97 for HPV16, 
and P99 for HPV31) is active in undifferentiated keratinocytes and serves as the 
initiation region for all early transcripts (Hummel et al., 1992; Smotkin et al., 
1989; Wang et al., 2011). The early genes are translated from a polycistronic 
mRNA that is polyadenylated from the early polyadenylation site at the end of 
the early gene region (Hummel et al., 1992; Remm et al., 1999). The expression 
of different genes from polycistronic mRNA is regulated by splicing. In the 
early region of the HPV11 genome, there are 3 splicing donor sites and 3 splic-
ing acceptor sites that in combination regulate the expression of all viral early 
proteins (Chiang et al., 1991; Chow et al., 1987a; Nasseri et al., 1987a; Roten-
berg et al., 1989a, 1989b). 
The late promoter (P674-714 for HPV11, P811 for HPV18, P670 for 
HPV16, and P742 for HPV31) is activated after the differentiation of the host 
cell and is situated just before the E1 start codon in the E7 ORF (Fig. 2, P674-
714) (Chow et al., 1987a; Hummel et al., 1992; Ozbun, 2002; Wang et al., 
2011). While the early promoter, P90, of HPV11 contains binding sites for the 
E2 protein within its sequence and is therefore regulated through the binding of 
the viral E2 protein, the differentiation-specific late promoter does not contain 
E2BSs and is E2-independent. Deregulation of the late promoter provides an 
environment to increase replication protein levels as well as amplify viral 
genome load by switching from theta replication mode to aggressive rolling 
circle replication mode. The late region genes encode viral structural proteins 
L1 and L2, which are expressed at the very end of the viral life cycle, just 
before capsid formation. Upon differentiation, use of the early poly-A site is 
reduced, and late mRNAs are polyadenylated from the late poly-A site and 






















































































































































































































































Chow et al. provided the first descriptions of HPV11 mRNA structures by char-
acterizing HPV-specific mRNAs obtained from a human anogenital condyloma 
via electron microscopic R-loop mapping (Chow et al., 1987a). The results were 
further confirmed and amended by other groups using a variety of methods, 
including PCR (Chiang et al., 1991; Rotenberg et al., 1989a), cDNA cloning 
(Nasseri et al., 1987a), nuclease mapping (DiLorenzo and Steinberg, 1995; 
Smotkin et al., 1989), retrovirus-mediated gene transfer (Chiang et al., 1991; 
Rotenberg et al., 1989b), and RACE analysis (Renaud and Cowsert, 1996). 
Analyzing the mRNAs collected from an anogenital condyloma, Chow et al. 
found that the majority of the transcripts have their 5´ends located at the end of 
the E7 ORF, and only a few species have their 5´ends just upstream of the E6 
ORF or within E1 ORF. Interestingly, 99.9% of the transcripts analyzed were 
polyadenylated in the early polyadenylation site, although the high copy number 
of the HPV11 genome and the use of the late promoter indicates that the infec-
tion might have reached the vegetative stage of the viral life cycle (Chow et al., 
1987a). However, the late polyadenylation site in the end of the L2 ORF was 
clearly used. This agrees with the general observation that LR-HPVs produce 
very few virus particles and that large amount of the viral capsid proteins L1 
and L2 are not needed. The most abundant transcript detected (98% of the 
cases) potentially encodes the viral fusion protein E1^E4, the functions of 
which are largely unknown. PCR analysis of HPV11 transcripts revealed that 
the E1^E4 protein could be encoded from two separate mRNAs: one ending at 
the early poly-A site and encoding only the E1^E4 protein and the other being a 
double-spliced late message for the major capsid protein L1, which also con-
tains the entire coding region for the E1^E4 protein (Rotenberg et al., 1989a). 
The possibility of internal reinitiation during translation and the potential of this 
late mRNA to encode the E1^E4 protein and the L1 protein could explain the 
high frequency of the E1^E4 transcript in the lesion analyzed.  
 
 
2.4 The HPV protein translation 
In this chapter, the translation of HPV18 E1 mRNA is described. Because of the 
high similarity among HPV genome organization, it is assumed that other HPV 
types use similar translation strategies. Translation of the largest HPV gene 
product, the replication protein E1, is a complicated process, as it is translated 
from polycistronic mRNA that includes coding sequences for E6 and E7 in 
front of the E1 ORF (Fig. 2, species I) (Plumpton et al., 1995; Remm et al., 
1999). According to the general paradigm, eukaryotic ribosomes translate the 
first coding sequence in mRNA most efficiently and continue at later cistrons 
with lower efficiency (Kozak, 1978, 1980). Although HPVs are quite conserved 
in terms of genome organization, there are some differences regarding the 
intron within the E6 ORF: HR-HPVs such as HPV16, HPV18, and HPV31 have 
an intron within the E6 ORF, whereas LR-HPVs such as HPV11 and HPV6 do 
not. However, splicing within this intron in the case of HR-HPV does not pro-
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duce monocistronic mRNA because the E7 ORF remains unaffected, leaving 
the E1 mRNA in an at least bicistronic state (Remm et al., 1999; Smotkin et al., 
1989). Interestingly, attempts to produce E1 protein from monocistronic mRNA 
in heterologous eukaryotic gene expression vectors have largely failed (Remm 
et al., 1999).  
Classical eukaryotic mRNA is monocistronic, and scanning of mRNA starts 
from the ultimate 5´ end and does not continue after the stop codon. However, 
translation of polycistronic mRNA is also possible, although this occurs at a 
lower efficiency (Kaufman et al., 1987). A variety of mechanisms have been 
proposed for the translation of polycistronic mRNAs in other small viruses. 
Ribosomal frameshift is a mechanism for the translation of overlapping retro-
virus proteins (Jacks et al., 1988). In cauliflower mosaic virus (Fütterer et al., 
1993) and adenovirus (Yueh and Schneider, 1996), a ribosome jumping mecha-
nism has been proposed in which the ribosome moves among different mRNA 
regions without scanning. Reinitiation or internal initiation has been proposed 
for the translation of non-overlapping picornavirus genes (Meerovitch and 
Sonenberg, 1993) and hepatitis B virus (Chang et al., 1989), and leaky scanning 
has been suggested to ignore the weak initiation codons for the translation of the 
hepatitis B virus P gene (Fouillot et al., 1993). 
Results of experiments with HPV18 reported by Remm et al. indicated that a 
discontinuous scanning mechanism drives the production of the E1 protein 
(Remm et al., 1999). In addition to other experiments that excluded some of the 
unusual scanning mechanisms of E1 polycistronic mRNA (e.g. read-through, 
and reinitiation), Remm et al. generated a series of mutant E1 plasmids with 
false ATG codons at increasing distances from the E1 start codon to determine 
how far in front of the E1 gene ribosomes scan mRNA. The nearest mutation of 
the real E1 ATG codon (45 nt away) had only a slight effect on levels of the E1 
protein, and other false ATG codons further away from the E1 gene had no 
effect on the translation of the E1 gene, indicating that mRNA scanning is dis-
continuous and happens only in front of the E1 gene (Remm et al., 1999).  
The E2 protein of papillomaviruses is translated from messages that lack the 
entire E1 ORF, but depending on the promoter that is used during mRNA tran-
scription, it may contain intact E6 and E7 ORFs in front of the E2 coding 
sequence (Fig. 2, species III-V). If the early promoter in front of the HPV11 E6 
ORF is used, the corresponding E2 mRNA will contain two exons: the first 
exon is composed of coding sequences for the E6 and E7 proteins, and the sec-
ond exon is composed of the full-length E2 ORF (Fig. 2, species III) (Chow et 
al., 1987a; Rotenberg et al., 1989b). The splicing from nt 847 to nt 2622 com-
pletely disrupts the E1 ORF. Mutating the splice acceptor site at nt 2622 dis-
rupts coding of the E2 protein, demonstrating that splicing is essential for the 
expression of E2 (Rotenberg et al., 1989b). Furthermore, deletion of the E2 
AUG start codon at nt 2723 demonstrated that this codon is indeed required for 
the functional expression of E2 (Hirochika et al., 1987). The full-length E2 pro-
tein can also be translated from mRNA in which transcription is started from the 
differentiation-dependent promoter in front of the E1 ORF (Fig. 2, species V). 
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In that case, the splicing pattern is the same as in the previously described E2 
mRNA, but the E6 and E7 ORFs are absent (Chow et al., 1987a; Rotenberg et 
al., 1989b). The lack of the N-terminal transactivation domain in the truncated 
form of E2 (E8^E2, also known as E2C) makes it an important inhibitor of HPV 
transcription and DNA replication (Chiang et al., 1991; Lim et al., 1998; 
McBride et al., 1991). The transcription of E8^E2 starts from a poorly described 
promoter region within the E1 ORF, which is then spliced from nt 1272 to nt 
3325 such that two exons are generated: the first exon includes the small E8 
ORF, and second exon includes the E2 C-terminal DNA binding/dimerization 
domain (Fig. 2, species II) (Chiang et al., 1991; Rotenberg et al., 1989a). The 
truncated form of the E2 protein competes with full-length E2 for DNA binding, 
which effectively downregulates DNA replication (Zobel et al., 2003).  
 
 
2.5 Papillomavirus life cycle 
2.5.1 Epithelial tissue complexity and its  
close relationship with the HPV life cycle 
The stratified epithelium is a very complex tissue composed of several cell 
types, including small numbers of melanocytes, Langerhans cells and Merkel 
cells, as well as differentiating keratinocytes (85% of the cells) that form lay-
ered sheets depending on the status of differentiation. The life cycle of human 
papillomavirus is tightly coupled to the differentiation process that the hosts, 
i.e., keratinocytes, undergo within the stratified epithelium (Fig. 3). There are 
two types of undifferentiated proliferating keratinocytes in the basal cell com-
partment, a few slow-cycling stem cells and transiently amplifying dividing 
cells that are the initial targets for PV infection and establishment of latent 
infection. To interact with basal proliferating keratinocytes, HPVs must first 
reach the basement membrane of the epithelium. An interaction between the 
carboxy-terminal part of the HPV L1 protein and host cell heparan sulfate and 
laminin 5 receptors is required for the effective infection of HPV (Giroglou et 
al., 2001; Joyce et al., 1999). Virus entry into the host cell is mediated via clath-
rin-dependent endocytosis (Day et al., 2003). Release of the HPV genome from 
the endosome as well as genome transport to the nucleus seem to be important 
additional roles of the viral L2 protein (Richards et al., 2006). After invading 
the cell nucleus, the HPV genome must undergo a few rounds of unlicensed 
replication to quickly increase the viral genome copy number. As soon as per-
sistent infection is established, papillomaviruses switch to a stable maintenance 
phase in which viral genomes replicate in concert with host cell DNA and are 
partitioned to daughter cells. In these cells, viral gene expression is kept at very 
low levels that are sufficient to replicate and maintain viral genomes, enhance 
cellular proliferation, and evade host immune defenses. When the basal cells 
divide, the daughter cells either remain in the basal layer and continue dividing 
or move upwards and begin the process of differentiation, which eventually 
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leads to complete stratification and to cell death. In the cells that differentiate, 
the third phase in viral infection is switched on; in this phase, viral late gene 
expression is activated and vegetative viral DNA amplification is initiated. 
Herein, large numbers of viral genomes are synthesized for packaging into viral 
capsids. One obstacle with this strategy is that HPVs need to synthesize viral 
DNA in differentiated cells, which normally exit the cell cycle upon differenti-
ation. HPV-positive suprabasal cells are able to override normal checkpoint 
controls and remain active in the cell cycle by expressing the E6 and E7 viral 
oncoproteins, which interact with host cell regulatory proteins, allowing for the 
synthesis of cellular replication factors that are necessary for viral DNA repli-
cation. It is believed that an additional important function of the E7 oncoprotein 
is the re-activation of host cell DNA replication machinery to support viral genome 
replication in terminally differentiated keratinocytes (Cheng et al., 1995).  
Figure 3. Simplified overview of the course of HPV infection in stratified epithelium. 
Healthy epithelium is shown on the left with keratinocyte differentiation stages. HPV-
infected epithelium is shown on the right, and the viral life cycle phases that are 
dependent on host cell differentiation are indicated. HPVs infect keratinocytes in the 
basal layer of the epithelium through microabrasions. After entering the host cell 
nucleus, the viral early genes are expressed, and the viral genome is amplified to estab-
lish a persistent infection. During the stable maintenance phase, viral protein expression 
is downregulated, and viral genomes are replicated in synchrony with host cell genetic 
material and divided almost equally between two daughter cells. After the differentia-
tion of an HPV-positive cell, the vegetative phase of infection is switched on. The 
expression of HPV oncoproteins alter cell cycle control and push a cell that normally 
would exit the cell cycle into S phase, allowing viral genome amplification. In the 
uppermost layers of the epithelium, viral structural proteins are expressed, viral 
genomes are encapsidated, and virions are released to the environment. The figure is 




2.5.2 Triphasic replication model for  
papillomavirus genome replication  
Depending on the differentiation status of infected cells, replication of the pap-
illomavirus genome can be characterized by three fundamentally different mechan-
isms: first, transient viral genome amplification replication; second, a stable viral 
genome maintenance replication and third, vegetative amplification replication.  
 
 
2.5.2.1 Transient amplification replication 
After invading to host cell viral genetic material is released into the host cell 
nucleus. The viral early promoter in the upstream regulatory region is activated, 
and the viral early proteins needed for cell transformation (E6 and E7) and for 
viral genome replication (E1 and E2) are expressed. To establish successful 
papillomavirus infection, the viral DNA copy number is quickly increased to 
approximately 50 to 100 copies per cell (Hebner and Laimins, 2006).  
Studies of different papillomaviruses have demonstrated that the E1 and E2 
proteins are the only viral proteins required for the initiation of DNA replication 
from the viral origin, which is located in the non-coding upstream regulatory 
region (URR) (Ustav and Stenlund, 1991; Ustav et al., 1991). The HPV viral 
replication origin contains four E2-specific palindromic motifs  
(5´-ACCGNNNNCGGT-3´, which corresponds to the E2 binding site, E2BS) 
and an adjoining A/T-rich sequence containing a binding site for the E1 protein 
(Piirsoo et al., 1996; Ustav et al., 1993, 1991). The minimal origin (MO) for 
replication initiation requires an A/T-rich sequence and one adjoining E2 bind-
ing site or two E2BSs alone (Lu et al., 1993; Sverdrup and Khan, 1995). Initia-
tion of viral DNA replication relies on the capacity of the E2 protein to specifi-
cally bind to the E2BS at the origin of replication and to simultaneously interact 
with the viral E1 helicase (Abbate et al., 2004; Androphy et al., 1987). The E1 
protein is recruited to the viral origin as a dimer, which is facilitated by E1-E2 
complex formation (Fig. 4) (Frattini and Laimins, 1994; Mohr et al., 1990; Sed-
man and Stenlund, 1995). When E1 binds to the E1BS at the A/T-rich segment 
in the URR, the E2 protein is displaced, and E1 forms a double-trimer complex 
(Sanders and Stenlund, 1998). The E1 double-trimer melts the dsDNA at the 
origin of replication, after which a double-hexamer is formed around each DNA 
strand (Fig. 4) (Schuck and Stenlund, 2005). The resultant E1 double hexamers 
are needed throughout the replication process as ATP-dependent replication 
helicases to unwind the DNA double-helix ahead of replication fork progression 
(Schuck and Stenlund, 2005; Wilson et al., 2002).  
During the nonproductive phase of infection, viral DNA replication is 
initiated bidirectionally via theta structures (replication intermediates that 
resemble the Greek letter “theta” – θ) at the replication origin. In this process, 
two replicating forks move away from the origin to drive DNA synthesis in the 
5´ to 3´ direction, with continuous synthesis of the leading strand and dis-
continuous synthesis of the lagging strand (Okazaki fragments) (Fig. 5) (Auborn 
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et al., 1994; Flores and Lambert, 1997). On a circular DNA molecule, the 
synthesis is terminated 180 degrees opposite of the initiation site, resulting in 
two daughter molecules, each of which has one strand from the parental DNA 
molecule and a second newly synthesized strand (Auborn et al., 1994; Flores 




Figure 4. A schematic overview of viral initiation complex assembly. Cooperative 
binding of the E1 and E2 proteins to the E1 and E2 binding sites (E1BS and E2BS) 
within the URR region results in the formation of a high-specificity E1:E2 complex. 
Adjacent E1 proteins are recruited to the complex such that double E1 trimers are 
formed and E2 proteins are released. Additional recruitment of E1 proteins is required 
for the conversion of the E1 trimers into double E1 hexamers, which have DNA hel-
icase activity. The figure is adapted from (Kurg, 2011). 
 
 
Since papillomaviruses are highly dependent on cellular replication machinery 
for doubling their genetic material, the E1 hexamers also serve as platforms for 
the assembly of host DNA replication factors such as DNA polymerase 
α/primase, replication protein A (RPA), and topoisomerases I and II (Chow and 
Broker, 1994; Clower et al., 2006; Masterson et al., 1998; Park et al., 1994; 
Titolo et al., 1999; Wilson et al., 2002).  
 
Figure 5. Simplified overview of bidirectional theta replication mode. Replication is 
initiated with the assembly of two replication forks at the origin of replication. The 
bidirectional progression of the replication forks converges 180 degrees opposite the 
initiation site, at which point the daughter molecules are separated and the replication 




2.5.2.2 Stable viral genome maintenance replication 
The initial amplification replication stage that occurs during the establishment 
of infection is believed to be rapid, and as soon as infection is ensured, papillo-
maviruses switch into the latent phase of infection. During latent infection in the 
basal and parabasal layers of the epithelium, the expression of viral replication 
proteins is downregulated, and the viral genome is replicated simultaneously 
with host cell genetic material (once per cell cycle). During mitosis, HPV 
genomes are attached to mitotic chromatids to ensure the effective segregation 
of synthesized HPV genomes into daughter cells. The partitioning of HPV 
genomes is mediated by the viral E2 protein, which simultaneously binds with 
E2BSs at the HPV URR region and with mitotic chromosomes to link viral 
genomes to host cell genetic material during cell division (Ustav et al., 2015). 
The latent phase of infection has been extensively studied in the HPV-posi-
tive cell lines W12-E and CIN612-9E, which were both isolated from naturally 
infected human tissues (Bedell et al., 1991; Stanley et al., 1989). Comparative 
studies of HPV replication during the latent phase of infection in W12-E and 
CIN612-9E cells revealed contradictory results: in the HPV16-positive W12-E 
cell line, a once-per-S-phase replication mode was observed, whereas viral 
DNA replication occurred via a random-choice mode in the HPV31-positive 
CIN612-9E cell line (Hoffmann 2006). In some cases, the replication of HPV31 
genomes in CIN612-9E cells was initiated more than once per S-phase, but 
some genomes replicated only once, and there was a fraction of viral genomes 
that failed to replicate. The random-choice replication mode in W12-E cells 
occurred when E1 protein levels increased, indicating that over-expression of 
the E1 protein is enough to overcome the restriction of once-per-S-phase repli-
cation during the latent phase of HPV16 infection (Hoffmann et al., 2006). 
When HPV16 and HPV31 genomes were transfected into the HPV-negative 
keratinocyte cell line NIKS, the random-choice replication mode was observed 
(Hoffmann 2006). The random-choice replication mode of HPV16 indicates 
that HPVs are capable of replicating by both replication mechanisms and that 
the mode of replication depends on E1 protein level and on the cells that harbor 
HPV episomes.  
 
 
2.5.2.3 Vegetative amplification replication 
When an infected basal cell divides and one of the daughter cells detach from 
the basal membrane, differentiation begins. Normally, these cells exit the cell 
cycle and stop dividing. However, cells that are infected with HPV continue the 
cell cycle, even those in the uppermost layers of stratified epithelia. This con-
tinued cycling is mediated by the viral oncoproteins E6 and E7, which alter cell 
cycle regulation and push cells into active cycling. These proteins therefore 
ensure that the host cell replication factors that are needed for viral DNA repli-
cation are continuously synthesized. During the vegetative phase of infection, 
viral episomes are amplified to high copy numbers, presumably through multi-
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ple rounds of replication in S-phase-arrested cells (Hoffmann et al., 2006). The 
high load of HPV episomes initiates the expression of the late capsid proteins 
L1 and L2, and single HPV genomes become encapsidated in viral particles 
(Frattini et al., 1996). The newly formed virions are then shed into the environ-
ment when the top layer of epithelium degrades. 
The mechanisms underlying the switch from the latent phase of infection to 
the vegetative phase are largely unknown. However, the processes that take 
place during the vegetative phase can be monitored in vitro under certain cul-
ture conditions that mimic the three-dimensional architecture of the stratified 
epithelium. The productive phase of HPV16 and HPV31b infection can be 
studied in the naturally infected keratinocyte cell lines W12-E and CIN612-9E, 
respectively. Suspending the cells in methylcellulose, using high-calcium 
medium or culturing the cells as organotypic rafts are three methods that induce 
host cell differentiation in vitro, allowing the extensive study of the final pro-
cesses that occur during the vegetative phase of infection. It has been suggested 
that a switch in the mode of DNA replication occurs during the productive 
phase of infection: in differentiated HPV16-positive W12-E cells, a switch to 
unidirectional rolling circle replication (RCR) has been suggested (Flores and 
Lambert, 1997). A study of replication intermediates (RIs) of HPV16 genome 
replication produced during the productive phase of infection indicated that 
DNA replication in this phase does not follow the bidirectional replication mode 
that is present during the initial genome amplification and latent phase of infec-
tion. Indeed, DNA structures detected via 2D AGE analysis correspond to the 
rolling circle replication mode (Flores and Lambert, 1997). Bubble and double 
Y-shaped DNA RIs, which are characteristic products that result when two rep-
lication forks move away from each other in bidirectional replication mode, 
were absent, and only Y-shaped replication intermediates, which are character-
istic of a unidirectional replication fork, a hallmark for rolling circle replication 
mode, were present (Flores and Lambert, 1997). The same replication mode has 
been presumed to occur in the differentiated HPV31-positive CIN612-9E cell 
line (Flores and Lambert, 1997). The switch to unidirectional replication mode 
may be a solution for escaping the unfavorable conditions that occur after host 
cell differentiation. While the theta replication mode requires initiation in every 
round of DNA replication, in rolling circle replication, one initiation event leads 
to the generation of multiple daughter DNA molecules. This method optimizes 
the use of already limiting levels of cellular factors for the generation of large 





Figure 6. (A) Simplified overview of unidirectional rolling circle replication mode. 
Replication is initiated at the double-strand (ds) origin with a site-specific nick. The free 
3´ end serves as a primer for DNA synthesis, while the unnicked strand serves as a 
template. Unidirectional replication proceeds with the simultaneous displacement of the 
non-template strand around the plasmid. Once the replication machinery reaches the 
initiation site, the displaced single strand is nicked at the 5´ end and recircularized. 
Leading-strand synthesis is completed when the replication complex returns to the ds 
origin. Replication is then initiated at the single-strand (ss) origin of the displaced 
strand. (B) Simplified overview of sigma-type rolling circle replication. The free 3´ end 
that serves as a primer for the replicative complex is generated by a site-specific nick. 
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The leading strand is synthesized with the simultaneous displacement of the non-tem-
plate strand. Upon reaching the initiation site, leading-strand synthesis is not terminated 
but proceeds for several rounds, generating long concatemeric tails. Discontinuous 
synthesis of the lagging strand in concert with leading-strand synthesis converts the 
newly synthesized ssDNA strand into dsDNA.  
 
 
Rolling circle replication mode is common for circular bacterial plasmids and 
ssDNA viruses. Unidirectional RCR requires one replication complex, which is 
formed on ssDNA through a site-specific nick (by the specific initiator protein 
Rep) of the dsDNA at the replication origin (Fig. 6A) (Ruiz-Masó et al., 2015). 
The free 3´-OH DNA end generated through the nick serves as a template for 
the replication complex, which extends the strand by moving from the 5´ to 3´ 
direction, with the simultaneous displacement of the non-template strand. The 
replication fork proceeds until the initiation/nicking site is reached, after which 
the leading-strand synthesis is terminated and the non-template strand is 
released from the newly synthesized molecule. For lagging-strand synthesis, the 
released ssDNA strand is used as a template, and dsDNA synthesis is initiated 
from a specific ssDNA replication origin (Ruiz-Masó et al., 2015).  
Sigma-type (σ-type) RCR generates multimeric linear dsDNA tails and can 
quickly amplify viral genomes. This replication mode is used during bacterio-
phage λ late replication (Bastia and Sueoka, 1975). In this mode, leading-strand 
synthesis is not terminated upon reaching the nick site but proceeds for several 
rounds, generating long concatemeric dsDNA tails (Fig. 6B). The lagging strand 
is synthesized simultaneously with the leading strand; otherwise, replication 
intermediates with ssDNA tails would be generated. 
 
 
2.6 Overview of cellular DNA damage response pathways 
Eukaryotic cells harbor two major DNA damage response (DDR) pathways to 
maintain intact genomic material during the duplication of their genetic mate-
rial. Activation of the DDR can originate from two types of DNA breakage: 
double-stranded and single-stranded breaks (DSBs and SSBs, respectively). 
DSBs activate the ataxia-telangiectasia mutated (ATM)-dependent pathway, 
which is characterized by the phosphorylation of ATM and its downstream 
effector kinase Chk2. SSBs, however, lead to activation of the Rad3-related 
(ATR) pathway, which results in activation of the ATR kinase and phosphory-
lation of its cognate downstream effector kinase Chk1. Upon their activation, 
the signal transduction of both checkpoint pathways triggers the activation of 
hundreds of proteins, primarily by phosphorylation at Ser/Thr-Glu motifs, that 
block cell cycle progression and facilitate DNA repair (Abraham, 2001; 




2.6.1 The ATM signaling pathway  
The ATM signaling pathway stalls the cell cycle to repair DSBs though two 
basic mechanisms: homologous recombination (HR) and non-homologous end 
joining (NHEJ). Which of these repair mechanisms is used depends on the 
phase of the cell cycle and on the nature of the DSB. HR is an “error-free” 
repair mechanism that is primarily used when a DSB is caused by a replication 
blockage in late S or G2 phase. NHEJ is an “error-prone” repair mechanism that 
is used when DSBs occur in packed chromosomes (Shrivastav et al., 2008). 
Since NHEJ is active during the entire cell cycle, the preference for HR during 
S and G2 phase is assured by different regulatory mechanisms. For example, 
one regulatory element between the HR and NHEJ pathways is the Mre11 
endonuclease, which is responsible for resectioning the DNA 3´ end at a DSB to 
activate HR and repress NHEJ (Dimitrova and de Lange, 2009; Shibata et al., 
2014). It is believed that when the homologous recombination pathway 
becomes compromised and cannot complete DNA repair, the repair process is 
switched to NHEJ.  
One reason why DSBs occur in S phase is replication fork collision during 
DNA replication. These breaks can be repaired via HR when sister chromatids, 
which sequences can be used as a template are available (Shrivastav et al., 
2008). The homologous recombination pathway is initiated when the MRN 
complex (Mre11-Rad50-Nbs1), which functions as a sensor for DSBs, registers 
a DNA break and resections the 3´ DNA end of the DSB through Mre11 endo-
nuclease activity (a crucial step in HR) (Dimitrova and de Lange, 2009; Shibata 
et al., 2014). Rad50 provides a protein scaffold that maintains the proximity of 
the two resectioned DNA ends (Hopfner et al., 2000; Williams and Tainer, 
2005). Subsequently, Nbs1 activates ATM kinase (Difilippantonio et al., 2005), 
which leads to the phosphorylation of a number of proteins, such as Brca1, 
Chk2, and p53, which mediate the effects of ATM on DNA repair, cell-cycle 
arrest, apoptosis, and other downstream processes (Maréchal and Zou, 2013). 
When DNA repair via HR is chosen, the resectioned ssDNA end invades the 
homologous sequence and through the mediation of a number of proteins (e.g., 
Rad51) forms a displacement loop (D-loop) structure (Fig. 7) (Krejci et al., 
2012). Finally, the replication complex is recruited onto the D-loop structure, 
DNA replication is initiated, and the break is repaired. The HR process takes 





Figure 7. Simplified overview of the two fundamentally different ATM pathways used 
to repair double-stranded DNA breaks. In homologous recombination, the resectioning 
of broken DNA ends and the alignment of the broken DNA with homologous sequences 
results in the reconstitution of the original sequence. In non-homologous end joining, 




Non-homologous end joining is used when DSBs result from the activity of 
endogenous factors (e.g., nucleases) or exogenous factors such as oxidative 
stress and ionizing radiation. In such cases, “clean” DSBs with complementary 
overhangs are available, and NHEJ can simply align and ligate two DNA ends 
together. NHEJ is a rapid process and functions throughout the cell cycle, as it 
does not require a homologous chromosome (Moore and Haber, 1996; Sonoda 
et al., 2006). However, when complementary overhangs are not available and 
DNA ends cannot be precisely rejoined, NHEJ typically generates small dele-
tions or sometimes small insertions by modifying the broken DNA ends 
(Shrivastav et al., 2008). Therefore, NHEJ may be the cause of genomic muta-
tions and can also cause genomic instability over time (Lieber, 2008).  
The NHEJ pathway is activated when a Ku70/80 heterodimer binds with 
DSBs that occur during G0, G1 or in early S phase (Lieber, 2008). Once the 
Ku-DNA complex is formed, the conformation of the Ku70/80 heterodimer 
changes to promote interactions with other key components (nuclease, polymer-
ases and ligase) (West et al., 1998). After the formation of Ku:DNA end com-
plex Ku interacts with endonuclease complex Artemis-DNA-PKcs. The auto-
phosphosylation of DNA-PKcs triggers the conformational change in DNA-
PKcs that regulates the access and also the endonuclease activity of Artemis to 
the DNA overhangs (Goodarzi et al., 2006; Meek et al., 2004; Uematsu et al., 
2007). To complete repair process of the broken DNA end via NHEJ, the poly-
merases µ and λ, and the ligase complex of XLF-XRCC4-DNA ligase IV are 
recruited to the DNA end repair complex (Ahnesorg et al., 2006; Lieber, 2008). 
Since, NHEJ repairs DSBs through various scenarios, the enzymes that drive 
the NHEJ pathway have to be flexible in function.  
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2.6.2 The ATR signaling pathway 
To ensure that each DNA replication origin is used only once per cell cycle, 
eukaryotic cells have acquired several origin licensing mechanisms. If the DNA 
re-replication is initiated during S phase and the accumulation of ssDNA or 
ssDNA-dsDNA junctions occurs, the ATR signaling pathway is activated (Liu 
et al., 2007). The quick response of the ATR checkpoint implies that ATR 
detects abnormal chromosomal structures at the initial steps of DNA re-replica-
tion and suppresses re-replication immediately after it is activated. The ATM 
checkpoint pathway, however, is activated at a much later stage, presumably 
after the ATR-mediated pathway has become compromised. The inhibition of 
re-replication is very important to avoid re-replication forks from running into 
leading forks, as it generates unfinished DNA fragments that are highly 
recombinogenic and may cause chromosomal rearrangements (Liu et al., 2007).  
RPA-coated ssDNA is the key structure that recruits the ATR-ATRIP (ATR 
interacting protein) complex to damaged DNA. In response to these events, 
ATR phosphorylates not only its effector kinase Chk1 but also many other 
downstream proteins, such as p53, Brca1, and Rad17, which collectively inhibit 
DNA replication or mitosis and promote DNA repair and recombination (Zou 
and Elledge, 2003). ATR also directly inhibits DNA re-replication by 
phosphorylating the RPA2 and MCM2 proteins, which are essential for DNA 
unwinding and during DNA replication initiation and elongation (Liu et al., 
2007). The phosphorylation of the RPA2 subunit prevents RPA from localizing 
to replication centers, and the replication initiation and elongation by RPA is 
subsequently compromised (Olson et al., 2006; Vassin et al., 2004). MCM2 
helicase activity is inhibited when ATR site-specifically phosphorylates MCM2 
at S108 in response to multiple forms of DNA damage and stalling of replica-
tion forks (Cortez et al., 2004). 
 
 
2.6.3 Recombination-dependent DNA replication mode 
Recombination-dependent DNA replication mode (RDR, also known as break-
induced replication [BIR] in yeast) can be associated with sigma-type rolling 
circle replication (Weller and Sawitzke, 2014a). RDR couples a unidirectional 
replication mode and the homologous recombination pathway, providing a 
mechanism for the maintenance of chromosome ends in budding yeast and in 
other eukaryotes that lack telomerase activity (Llorente et al., 2008). Prokary-
otes with linear DNA also use RDR to finish replicating linear DNA ends. RDR 
replication has been characterized in E. coli (Kuzminov, 1995), in bacterio-
phage SPP1 (infects Bacillus subtilis) (Lo Piano et al., 2011), during the 
bacteriophage T4 late replication step (Kreuzer and Brister, 2010; Liu and 
Morrical, 2010), and in herpes simplex virus (Weller and Sawitzke, 2014b).  
RDR also contributes to the rescue of collapsed replication forks (RFs) that 
generate dsDNA breaks with ssDNA overhangs. RDR is initiated by the inva-
sion of a single strand into a homologous DNA molecule, followed by the 
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assembly of anew replication fork, after which DNA replication is initiated. 
Normally, the RF is disassembled and the elongation of DNA replication is 
finished when the break is repaired, but in RDR, the end of the invading single 
strand can be extended for hundreds of kilobases and DNA synthesis can pro-
ceed until the end of the chromosome is reached (Malkova and Ira, 2013).  
The initial steps in the induction of RDR overlap with the induction of the 
HR repair pathway in many aspects. Recombination-dependent replication of 
dsDNA breaks requires a free 3´ end to trigger the initiation of leading-strand 
synthesis. Similarly to HR, the resectioning of free 3´ DNA ends is mediated by 
Mre11 nuclease (in eukaryotic cells) (Shibata et al., 2014). The resultant  
3´-ssDNA overhangs act as substrates for strand invasion mediated by RecA in 
bacteria or by Rad51 in eukaryotes and ultimately form a D-loop structure (Asai 
et al., 1993; Davis and Symington, 2004; Malkova et al., 2005). The mecha-
nisms driving replication fork assembly and DNA synthesis have been studied 
in great detail in bacteria. In bacteria, the D-loop structure is recognized by the 
mediator protein PriA, and with the help of other proteins, the replicative hel-
icase dnaB and the primase dnaG are loaded onto the D-loop structure (Marians, 
2000). Once the helicase and primase are loaded, the polymerase Pol III is 
recruited, and DNA synthesis of the leading strand is initiated. The lagging 
strand is synthesized synchronously with the leading strand (Kreuzer, 2000). In 
eukaryotes and yeast, the process of replication fork assembly is not well under-
stood. Initial studies of BIR in yeast have shown that almost all of the factors 
that are essential for regular replication initiation in S-phase as well as for 
unwinding of the DNA double helix (Mcm2-7) are also needed in BIR (Lydeard 
et al., 2010). Only the components that are exclusively needed for formation of 
the pre-replication complex (cdc6 and Orc) are dispensable in BIR (Lydeard et 
al., 2010).  
 
 
2.7 The connection between HPV replication and  
the cellular DNA damage response  
Cellular DNA damage response pathways are often activated by active viral 
DNA replication as replication intermediates are sensed as aberrant DNA mole-
cules (Lilley et al., 2005; Stracker et al., 2002). Additionally, various viral pro-
teins induce the DNA damage response and produce replication stress by inter-
fering with cell cycle regulation (Bester et al., 2011). Viruses have adapted 
mechanisms to address such host responses and intervene or inactivate cellular 
pathways that might hinder viral DNA replication. Likewise, viruses are also 
able to take advantage of host defenses, such as the ATM and ATR pathways, 
in various aspects of viral DNA replication (Chaurushiya and Weitzman, 2009). 
In human papillomaviruses, the activity of the E1 protein is sufficient to 
induce cell cycle arrest and activate cellular DDR pathways (Fradet-Turcotte et 
al., 2011; Sakakibara et al., 2011). The ATPase/helicase and origin-binding 
functions of E1 and its nuclear accumulation cause early S-phase arrest and 
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activate the DNA damage response, specifically the ATM pathway (Fradet-
Turcotte et al., 2011). To prevent cell cycle arrest during the maintenance phase 
of the viral genome in undifferentiated cells, E1 has to be maintained in the 
cytoplasm, being transported to the cell nucleus only when it is required for 
DNA replication (Fradet-Turcotte et al., 2010, 2011; Yu et al., 2007). The for-
mation of the E1-E2 protein complex balances the induction of the DDR by E1, 
as E2 reduces the nonspecific binding of E1 but does not prevent E1-induced 
cell cycle arrest. In ATM-deficient cells, in which activation of the DDR path-
way is compromised, E1 still inhibits the cell cycle (Fradet-Turcotte et al., 
2011). It seems that the capacity of E1 to trigger cell cycle arrest and activate 
DDR pathways are two mechanistically distinct events. Interestingly, inhibition 
of the ATM pathway has no effect on viral DNA replication during the latent 
phase of HPV infection, although activation of the ATM pathway can be clearly 
detected (Moody and Laimins, 2009). More importantly, although the ATM 
pathway is dispensable during the latent phase, it is essential for amplification 
of the viral genome during the vegetative phase of infection; inhibition of the 
ATM pathway completely blocks HPV genome amplification in differentiated 
cells (Moody and Laimins, 2009). While some viruses, such as adenovirus, 
delocalize or degrade components of the MRN complex (Stracker et al., 2002), 
HPV maintains them at high levels throughout the vegetative phase (Moody and 
Laimins, 2009). The active phosphorylation of Chk2 (an important transducer 
of the ATM signaling pathway), Nbs1 and Brca1 (both of which play important 
roles in DNA repair and in regulating S and G2 checkpoints) as well as the co-
localization of these effectors to HPV replication foci indicates the important 
role of the MRN complex during the vegetative phase of HPV infection. In dif-
ferentiated cells, where the levels of cellular components needed for DNA repli-
cation are limited, the activation of DNA repair mechanisms is very beneficial, 
as all the components required for DNA synthesis are then delivered to viral 
recombination/replication foci. Additionally, activation of the ATM pathway 
induces S or G2/M cell cycle arrest, which provides an environment that allows 
multiple rounds of viral genome re-replication. 
The importance of homologous recombination proteins in active HPV DNA 
replication centers has raised the question what mode of replication occurs dur-
ing the vegetative phase of replication. Although clear evidence shows that 
there is a switch from bidirectional theta replication to unidirectional replication 
after host cells are induced to undergo differentiation (Flores and Lambert, 
1997), mechanisms other than rolling circle replication may be involved in the 
duplication of HPV genomes during the vegetative phase of infection. Several 
HPV replication intermediates that are characteristic to recombination-depend-
ent replication give rise to the possibility that homologous recombination-
related DNA replication may play a role in HPV DNA duplication during the 
vegetative phase of infection (Sakakibara et al., 2013). RDR is a combination of 
unidirectional replication and homologous recombination, which govern the 
conditions that occur during the vegetative phase of infection. Additionally, the 
possibility to extend DNA replication for hundreds of kilobases makes RDR an 
33 
efficient and attractive way for viruses to quickly amplify their genetic material. 
For circular DNA molecules, RDR can give rise to concatemeric DNA multi-
mers that must later (in the case of HPV) be processed into unit-sized circular 
genomes. Oligomeric forms of the HPV genome have been shown to be present 
in various transiently transfected cell lines (Orav et al., 2013), and HPV oligo-
mers have also been detected in clinical samples obtained from patients with 
permanent HPV infection (Boshart et al., 1984; Cullen et al., 1991; Dürst et al., 
1985; Orav et al., 2013). The involvement of recombination-dependent replica-
tion in the production of HPV oligomers is suggested to occur as the combina-
tion of heterogenic HPV molecules within the formed oligomers was observed 
(Orav et al., 2013).  
The possible connection between the non-homologous end joining repair 
pathway and HPV DNA replication is still controversial. While the ATR factor 
DNA-PK does not exhibit significant co-localization to HPV genome replica-
tion centers (Gillespie et al., 2012), clear co-localization of the Ku70/80 hetero-
dimer to HPV replication foci has been detected (Kadaja et al., 2009). Because 
the homologous recombination pathway seems to be the most prevalent path-
way during S and G2 phase, NHEJ may serve as an alternative for the repair of 
DSBs when HR is somehow compromised. Additionally, because NHEJ is an 
“error-prone” mechanism that may generate rearranged genomes, it is probably 
beneficial for HPV to not use this pathway for the repair of DNA breaks. 
In addition to the ATM pathway, the ATR pathway also responds to DNA 
replication stress and is likely to be involved in HPV genome replication. The 
key components of the ATR pathway, namely, ATR-interacting protein 
(ATRIP) and topoisomerase IIβ-binding protein 1 (TopBP1), have been shown 
to co-localize at HPV replication centers during initial amplification of the viral 
genome (Kadaja et al., 2009; Reinson et al., 2013). Additionally, localization of 
the DNA damage response marker γH2AX to viral replication centers indicates 
the possibility that the ATR pathway is activated.  
 
 
2.8 Physical state of HPV DNA during infection and the 
progression from normal virus infection to cervical cancer 
Permanent HPV infection is the most significant event in the malignant trans-
formation of human cervical epithelium. The progression from benign cellular 
changes to invasive cancer is graded from the formation of a low-grade squa-
mous intraepithelial lesion (LSIL, cervical intraepithelial neoplasia CINI) to a 
high-grade squamous intraepithelial lesion (HSIL, CINII and CINIII). The pro-
gression from stage CINIII to squamous cell carcinoma (SCC) exclusively 
occurs as the result of an untreated infection. However, not all HSILs progress 
to invasive cancer: approximately 35% of HSILs undergo complete regression 
in a time frame of 4-6 months (Melnikow et al., 1998; Trimble et al., 2005). The 
physical state of the HPV genome in these lesions is highly dependent on the 
type of HPV and on the differentiation stage of the infected tissue (Hudelist et 
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al., 2004). Generally, normal infection proceeds through the episomal HPV 
molecules, and the virus does not need to integrate into the host genome to be 
fully functional. In normal epithelium and in CINI/CINII stage tissues, the HPV 
genome exclusively exists as an extrachromosomal molecule. However, in stage 
CINIII tissues, subgenomic parts of HR-HPV genomes are often integrated into 
the host chromosome. In HPV18 and several other HR-HPVs (-31, -33, -52b, 
and -58), the progression to cervical cancer is highly dependent on the integra-
tion step (Hudelist et al., 2004), as cells carrying integrated HR-HPV gain a 
growth advantage due to cell immortalization (Jeon et al., 1995; Romanczuk 
and Howley, 1992). At the same time, HPV16 genomes are generally found 
both in an episomal form and in a mixed episomal/integrated form and are 
rarely found only in an integrated form in cervical biopsy probes (Arias-Pulido 
et al., 2006).  
In cancer cells, the HPV genome is found integrated into the host chromo-
some in a way that approximately half of the HPV genome is lost. Extensive 
mapping of the integration locus of HPV16 has revealed that the viral genome is 
primarily disrupted within the HPV16 E2 hinge region (Arias-Pulido et al., 
2006). Disruption of the E2 ORF releases the repressor activities of this gene 
product on the E6 and E7 oncogenes. The increased expression of the E6 and 
E7 proteins, which bind and inactivate p53 and pRB-family proteins, leads to a 
growth advantage of the affected cells (Jeon and Lambert, 1995; Jeon et al., 
1995; Romanczuk and Howley, 1992). In HPV16, however, where strict 
integration occurs in a low percentage of tumors and the viral genome typically 
exists as both an episomal and integrated form, the E2 protein may regulate E6 
and E7 expression in trans, and a growth advantage of cells carrying only inte-
grated forms of the HPV16 genome may not be detectable (Arias-Pulido et al., 
2006). Using a W12-E culture model, Pett et al. demonstrated the coexistence of 
episomal and integrated HPV16 DNA in the same cell during early passages 
and the subsequent loss of episomal plasmids in later passages (Pett et al., 
2006). The loss of E2-expressing HPV plasmids resulted in a growth advantage 
and in the spontaneous selection of cells containing only integrated HPV16 
(Pett et al., 2006). Similar results were obtained with cells carrying a single 
copy of integrated HPV33 (Peitsaro et al., 2002). 
LR-HPVs, like HPV6 and HPV11, do not tend to integrate into cellular 
DNA and have only been detected in an episomal form regardless of lesion 
grade. 
The integration locus on the host chromosome has also been the focus of 
several studies. Analysis of cervical tumor probes revealed that HPV integration 
sites are randomly distributed over the whole genome, with a clear preference 
for genomic fragile sites (Thorland et al., 2000; Wentzensen et al., 2004). Frag-
ile sites are transcriptionally active sites, intragenic regions or gene-dense 
regions that, under appropriate culture conditions or exposure to certain chemi-
cal agents (e.g., aphidicolin, a DNA polymerase inhibitor), exhibit a tendency to 
form chromosome or chromatid gaps and breaks or other chromosomal abnor-
malities. The lack of replication origins in very long gene areas frequently cause 
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collisions of replication machinery, and cells often proceed to mitosis with 
incompletely replicated regions of DNA. In G2 phase, there needs to be a 
mechanism to keep chromatin open to DDR pathways to finish DNA replica-
tion/repair. The localization of the cellular chromosome-associated protein Brd4 
(bromodomain-containing protein 4) to fragile sites is believed to mediate the 
accessible chromatin environment (Jang et al., 2014). Brd4 is also an important 
cellular partner for papillomavirus E2 protein. The interaction of the E2 protein 
with Brd4 regulates the transcriptional activity of E2 and is also required to 
ensure the tethering of PV genomes to host mitotic chromosomes to ensure the 
persistence of viral episomes in infected cells (Baxter et al., 2005; Kurg et al., 
2006; You et al., 2004). In addition to the genome partitioning function of the 
E2-Brd4 interaction, it is believed that this complex also tethers viral replication 
foci adjacent to fragile sites (Jang et al., 2014). The association with fragile sites 
gives another opportunity for the virus to recruit the cellular DDR pathway, 
which is already activated by the replication stress occurring in fragile sites, to 
amplify viral genomes. However, by replicating its genome in the proximity of 
unstable chromosome regions, the virus greatly increases the chances of acci-
dental integration of viral DNA into these sites. 
The human genome contains a number of hotspots for HPV integration. For 
example, the region of the c-Myc gene at chromosomal position 8q24 is one site 
where HPV frequently integrates (Couturier et al., 1991). Structural alterations 
and/or overexpression of the c-Myc gene occur with high frequency in cervical 
carcinomas (Ocadiz et al., 1987; Riou et al., 1984), and amplification of the  
c-Myc gene in the HPV16-immortalized keratinocyte cell line resulted in an 
increased growth rate compared with the parental W12-E cell line (Crook et al., 
1990). MYC overexpression has been related to co-amplification of the Myc 
gene and integrated HPV sequences (Peter et al., 2006). A low level of MYC 
overexpression has been characterized in HeLa cells harboring integrated 
HPV18 sequences in chromosome band 8q24 (Dürst et al., 1987; Lazo et al., 
1989). A decrease in the levels of the myc gene product was observed in HeLa 
cells when an integrated HPV18 fragment located ~500 kbp downstream of the 
myc gene was knocked out, supporting the hypothesis that integration of HPV 
influences MYC expression via a long distance chromatin interaction (Zhang et 
al., 2016).  
 
 
2.9 Multiple HPV infections in cervical neoplasias  
Multiple human papillomavirus genotypes often coexist within infected epithe-
lia and are frequently detected together in samples of various grades of cervical 
neoplasia. For women, age is one of the most important factor associated with 
multiple HPV infection (Antonsson et al., 2014). There is a U-shaped curve for 
HPV prevalence versus age, with the highest multiple infection rate being found 
among women 55 or older, followed by women younger than 25 (Wang et al., 
2016; Yip et al., 2010). In contrast, the single HPV infection rate is highest 
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among women who are 25-34 years old (79%) (Wang et al., 2016). Multiple 
infection among young women might result from high levels of sexual activity 
and has also been associated with the ongoing development of HPV-type-spe-
cific acquired immunity (Kjaer et al., 2000; Schiffman and Castle, 2003). 
Among older women, fluctuations of menopausal hormones along with 
decreased immunity and diminished ability to eliminate and inhibit the virus 
may together play an important role in multiple HPV infection (Althoff et al., 
2009).  
A study of the prevalence of multiple infections with HR-HPV genotypes 
found that in 65% of the cases in Northern China, the most common arrange-
ment of multiple infection was HPV16 in combination with other HR-HPVs 
(Wang et al., 2016). Single HPV infection was found in 25% of the samples. 
The frequency of multiple HPV infections in Northern China were highest in 
inflammatory cervical samples (41.0%), followed by cervical cancer (15.7%), 
CINI (7.2%), and CINII–III (1.2%) (Wang et al., 2016).  
The clinical importance of multiple infections in the progression of cervical 
neoplasia remains a controversial area of investigation. In some studies, these 
infections have been associated with a high risk for the development of cervical 
cancer (Cuschieri et al., 2004; Herrero et al., 2005; Pista et al., 2011; Spinillo et 
al., 2009; Trottier et al., 2006), whereas other studies have reported no increased 
risk for CIN compared with single-type infections (Kay et al., 2003; Levi et al., 
2002; Muñoz et al., 2003; Sandri et al., 2009; Wang et al., 2016). 
Due to the limited technical capabilities for identifying multiple infections in 
the same cell, double infection cases have thus far only been identified in the 
same tissue probe. However, under laboratory conditions, the expression of 
HPV replication proteins in cell lines harboring integrated HPV sequences 
induces overamplification of the genomic locus where the HPV origin has been 
integrated (Kadaja et al., 2007). It is possible to show that transfected HPV 
circular genomes are not only replicating in HeLa and SiHa cells but also mobi-
lize the integrated HPV origin for DNA replication, which leads to the induction 
of genomic rearrangements within the integrated locus. Overamplification can 
cause excisions, rearrangements and de novo integration of the replication prod-
ucts of integrated HPV and flanking cellular sequences.  
Additionally, irrespective of the type of integrated HR-HPV, other types of 
HPV replication proteins, including LR-HPV types (HPV6b and HPV11), can 
also induce DNA replication from an integrated HPV replication origin (Kadaja 
et al., 2007). Therefore, integration of HR-HPV and episome loss may silence 
an HPV infection, allowing a cell to be re-infected by a new virus. The possi-
bility of double infection of cells harboring integrated HPV sequences causing 
genomic instability may contribute to the formation of HPV-related cervical 




2.10 In vitro cell culture systems to study  
HPV gene expression and viral DNA replication 
Papillomaviruses are extremely host- and tissue-specific and infect cells in the 
basal layer of stratified epithelia. The three-step life cycle of PV can be 
mimicked in organotypic cell culture models that undergo differentiation. These 
cultures are prone to spontaneous differentiation and are therefore quite variable 
in culture conditions; furthermore, maintaining the cultures is time consuming 
and very expensive. The lack of suitable cell culture systems has hindered the 
study of different aspects of human papillomavirus infection. Preliminary 
knowledge about papillomavirus gene expression, individual viral protein func-
tions and viral DNA replication has been collected from studies of bovine pap-
illomavirus type 1 in the mouse fibroblast cell-line C127, transformed by the 
BPV1 oncoprotein E5, which turned out to be a suitable model system (Law et 
al., 1981; Neary and DiMaio, 1989; Yang et al., 1985). Although there are 
differences in genomic organization and host preference, the overall structure of 
the papillomavirus genome is very conserved. Therefore, information gained 
from BPV1 studies, including the basic mechanisms of viral gene expression, 
the interactions of viral cis and trans elements (Abroi et al., 1996; Kurg et al., 
2006; Piirsoo et al., 1996; Sedman et al., 1997), the modes of DNA replication 
and the regulation thereof (Männik et al., 2002; Ustav and Stenlund, 1991; 
Ustav et al., 1993), and the segregation to daughter cells (Piirsoo et al., 1996), 
can be taken as a general principle when studying HPV.  
The development of virus-like particles (VLPs) for various viruses has 
offered the opportunity to study the initial steps of viral infection as well as 
interactions between virus and host cell for basic and clinical research. How-
ever, the development of infectious HPV pseudovirions in native organotypic 
cultures has had very little success. The methods used are technically demand-
ing, time-consuming, and variable, and they produce relatively low virus yields 
(Dollard et al., 1992; McLaughlin-Drubin et al., 2003, 2004; Meyers et al., 
1992). In recent years, methods to produce papillomavirus pseudovirions inde-
pendent of epithelial cell differentiation have been developed (Buck et al., 2004; 
Pyeon et al., 2005). As a first approach, BPV1 capsid proteins were expressed 
from expression vectors in transiently transfected 293TT human embryonic 
kidney cells, and the reporter plasmids were encapsidated into bovine papillo-
mavirus VLPs (Buck et al., 2004). However, there is a strong limitation on the 
size of a target plasmid, as only DNA ranging from 6 to 7 kbp in size can be 
packed into pseudovirions, which is much less than the natural viral genome 
size of approximately 8 kbp. A second approach enables the encapsidation of 
full-length papillomavirus DNA into HPV16 VLPs using the same 293T(T) cell 
line as the previous study (Pyeon et al., 2005). Pseudovirions resulting from this 
approach were highly infectious toward their natural host, epithelial cells: they 
were >1000 times more infectious than pseudoviruses isolated from the labor-
intensive and time-consuming organotypic raft culture method. Why one of 
these approaches leads to the encapsidation of the full-length HPV genome or a 
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same-size reporter plasmid into virus particles and the other results in the pack-
aging of a shortened genome is unknown. Presumably, either HPV16-based 
VLPs have different packaging constraints than BPV1-based VLPs or differ-
ences in the DNA being packaged contribute to differences in packaging effi-
ciency (Pyeon et al., 2005). The development of HPV VLPs is crucial for 
understanding how papillomaviruses interact with receptors at the cell surface, 
enter the cell, and infect the cell, but applying this approach for other HPV 
research purposes has not been successful. Therefore, other methods (e.g., elec-
troporation, lipofection) have been used to effectively transport viral DNA into 
cells in culture.  
For HPV, a number of immortalized epithelial cell lines have been devel-
oped that enable short-term DNA replication studies and gene expression analy-
sis. Monolayer epithelial cell lines containing integrated HR-HPVs, such as 
HeLa (HPV18-positive), SiHa (HPV16-positive) and CaSki (HPV16-positive) 
cells, were obtained from samples of naturally infected human cervix. HPV-
negative cell lines, such as the C33A and 293 lines, that support the expression 
of HPV proteins and DNA replication from heterologous plasmids are all con-
venient and cost-effective model systems to identify the cis elements necessary 
for initiation of viral DNA replication and to study transient viral DNA replica-
tion and viral protein expression and function. Co-transfection of E1 and E2 
expression plasmids and an URR-containing plasmid allowed monitoring of the 
effects of E1 and E2 to episomal URR plasmid replication as well as to inte-
grated HPV URR (in HPV-positive cell lines) (Kadaja et al., 2007). However, 
expressing these viral proteins in near-native concentrations and monitoring of 
viral genome replication are still quite challenging in these cells.  
Primary human foreskin keratinocytes (HFKs) are considered the most rele-
vant native host cells for HPV infection and have therefore been widely used. 
Transfection of HFKs with different HR-HPV types results in a high frequency 
of cells that maintain viral genomes as extrachromosomal elements (Frattini, 
Lim et al. 1996; Frattini, Lim et al. 1997). The growth of these cells in organo-
typic cultures enabled the monitoring of differentiation-dependent expression of 
viral late genes, viral genome amplification, and virion biosynthesis. Ironically, 
however, these cells are extremely difficult to infect, as they have high levels of 
basal autophagy, which serves as a host defense pathway to inhibit HPV infec-
tion (Griffin et al., 2013). Additionally, HFKs should not be cultured for longer 
than 4 weeks, as significant morphological changes and growth arrest occur 
after 6 weeks (Griffin et al., 2014). Moreover, the isolation of primary human 
keratinocytes from various patients with different genetic backgrounds may 
produce different results with regard to HPV research.  
Normal immortalized keratinocytes from skin (NIKS) is another physiologi-
cally relevant cell culture model that has been used to investigate HPV infec-
tion. NIKS are a spontaneously immortalized near-diploid cell line that has a 
normal growth and differentiation program (Allen-Hoffmann et al., 2000). As 
immortalized cells, establishment of genetically modified stable cell lines is 
possible. However, NIKS are quite difficult to culture compared to HFK or 
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HaCaT cells, as they require feeder cells and various growth factors to support 
healthy growth without spontaneous differentiation.  
The spontaneously immortalized HaCaT cell line has been widely employed 
as a keratinocyte cell model due to its ease of use and near-normal phenotype. 
Under typical culture conditions, HaCaT cells have a partially to fully differen-
tiated phenotype due to high calcium concentrations in standard media and in 
fetal bovine serum (Deyrieux and Wilson, 2007). While HaCaT cells might be 
useful for initial experiments, data obtained from these cells should be further 
confirmed with normal keratinocytes, such as NIKS or HFKs. 
Two organotypic cell culture systems established from naturally infected 
human cervical tissues have become powerful tools for studying the stable and 
vegetative life cycle phases of the two HR-HPV types (HPV16, HPV31) that 
originally infected these cells. The first, HPV16-positive W12-E cell line was 
isolated from a low-grade cervical lesion (CINI) that in early passages main-
tains HPV16 genomes as extrachromosomal molecules at approximately 100 to 
200 copies per cell and exhibits a typical keratinocyte morphology. But when 
grown in the flank of a nude mouse, an epithelial lesion with CINI/II histologi-
cal features is formed (Stanley et al., 1989). Ultrastructural analysis of the 
lesion indicated that the tissue had stratified morphology and exhibited charac-
teristics of differentiation. The lower layer of the lesion contained undifferenti-
ated cells with normal nuclei, the upper layer contained condensed nuclei and 
keratin bundles, and the uppermost layer had lost cell nuclei (Flores and 
Lambert, 1997). Therefore, the W12-E cell line is a valuable culture system that 
represents an accurate keratinocyte differentiation model and thus allows mon-
itoring of the carcinogenic progression of HPV16-associated infection. How-
ever, long-term cultivation of W12-E cells generally leads integration of the 
HPV16 genome, which ultimately results in the complete loss of episomal 
HPV16 genomes (Stanley et al., 1989). Therefore, to obtain reproducible 
results, the physical state of HPV16 episomes needs to be specified prior to any 
analysis.  
The second organotypic cell line derived from a CINI lesion contains epi-
somal HPV31b genomes and is called CIN612-9E. These cells differ from 
W12-E cells in that they do not stratify when maintained in high-calcium and 
high-serum medium (Flores and Lambert, 1997). However, when suspended in 
semisolid medium and grown at the air-liquid interfaces of in vitro collagen raft 
cultures, the cells differentiate and histologically resemble a low-grade cervical 
lesion (Bedell et al., 1991; Flores and Lambert, 1997). In the CIN612-9E cell 
line, the progression of HPV31b-associated infection can be followed, with a 
switch in the mode of replication being observed upon differentiation (Flores 
and Lambert, 1997). Amplification of the HPV31b genome is observed in dis-
tinct foci in the upper layer of the stratified epithelium, but no capsid protein 
synthesis can be detected, despite the presence of transcripts from the late 
region of HPV-31b (Bedell et al., 1991).  
Due to the low oncogenic activity of LR-HPV E6 and E7 proteins, no 
immortalized LR-HPV-positive cell lines are available. Most knowledge of 
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low-risk HPV types has been gained by transfecting already immortalized 
human keratinocytes or other cell lines capable of supporting viral DNA repli-
cation and gene expression (Del Vecchio et al., 1992; Fang et al., 2006; Mungal 
et al., 1992; Thomas et al., 2001). The development of organotypic cultures 
carrying LR-HPV genomes has not been effective, as LR-HPVs do not immor-
talize cells in vitro, although they have been shown to increase the life span of 
infected cells (Thomas et al., 2001).  
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3. OBJECTIVES OF STUDY 
The transformation of HPV-infected cell into a genetically unstable cancer cell 
is believed to be triggered by the viral integration to a host chromosome. The 
mechanisms underlying the integration of HPV DNA are not well understood, 
however, the generation of abberant DNA molecules during HPV DNA replica-
tion and the co-localization of DDR pathway key components to HPV DNA 
repair/recombination centers may play a role in this process. Moreover, viral 
DNA integration encompasses only a few viral genomes, while the majority 
remain extrachromosomal molecules. The co-occurrence of two forms of viral 
DNA in one cell is a real threat to genomic stability, as episome-derived repli-
cation proteins can initiate DNA replication also from the integrated HPV origin 
of replication. 
Although HPV vaccines that successfully prevent infection of 9 HPV types 
have been developed, there remains an unmet need for anti-viral drugs that can 
cure women and men who are already infected with HR-HPV. Whilst, infection 
with LR-HPV seems less important due to its low oncogenic activity, it still 
causes women to suffer under discomfort, and therefore the development of 
drugs to treat the infection is also relevant. Currently, approximately 8 billion 
dollars are spent annually to cure HPV infection in the US alone. The develop-
ment of anti-viral drugs has been hindered for years because of the lack of suit-
able and cost-effective cell culture systems that would enable the screening of 
thousands of chemical compounds that might target the vital functions of the 
virus. Currently available native organotypic keratinocyte cell culture models 
for the study of papillomaviruses are quite unstable, as they are very sensitive 
regarding the availability of feeder cells and various growth factors that can 
support healthy growth without causing spontaneous differentiation. It has been 
our goal for several years to develop a simpler system for the study of different 
papillomaviruses and for the future screening of chemical compounds. The gen-
eral aim of our group has been to search for an HPV-negative monolayer cell 
line that is cost-effective, robust in culture, has high transfection efficiency and 
viability, and effectively replicates the HPV genome at near-native protein lev-
els. Transfection of HPV genomes into previously used immortalized epithelial 
cell lines (e.g., HeLa, SiHa, CaSki, and HaCaT) did not meet this goal as very 
large quantities of transfected DNA are needed to monitor HPV genome repli-
cation at detectable levels. 
The general objectives of this thesis were to further characterize the useful-
ness of the human osteosarcoma cell line U2OS for molecular studies of HPVs 
and to elucidate the factors surrounding genomic instability in HPV-positive 
cell lines in the presence of HPV replication proteins.  
The specific goals of my studies were as follows: 
1) To explore the consequences of host cell genomic DNA re-replication 
after the initiation of HPV E1 and E2 protein-dependent DNA replication 
from an integrated HR-HPV origin  
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2) To investigate the physical state of HPV16 and HPV18 genomes in 
patient clinical samples 
3) To study the transient, stable and amplificational replication of HPV6b 
and HPV11 in U2OS cells and to produce and characterize stable cell 
lines harboring episomal HPV6b and HPV11 genomes  
4) To compile a complete transcriptome map of HPV11 in U2OS cells, 
thereby providing additional reliability for the use of U2OS cell-based 
assays for HPV research 
5) To elucidate the importance of the E6/E7 leader sequence in front of the 
HPV11 E1 ORF for the synthesis of stable and functional E1 protein 
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4. MATERIALS AND METHODS 
The materials and methods used in this thesis are described in detail or referred 
to in the primary source within the associated research articles. As most of the 
experiments presented in this thesis were performed using U2OS cells, the cell 
line and methods used for handling the cells are briefly described herein. 
The U2OS (originally 2T) line is derived from a moderately differentiated 
sarcoma of the tibia from a 15-year-old girl in 1964 and exhibits an epithelial 
cell-like morphology with functional tumor-suppressor genes p53 and reti-
noblastoma protein pRb, which are often mutated in cancer cell lines (Isfort et 
al., 1995; Ponten and Saksela, 1967; Wesierska-Gadek and Schmid, 2005). 
Characterization of oncogenes in U2OS cells revealed increased expression of 
the c-myc oncogene positioned in the 8q24 chromosome band (Isfort et al., 
1995). U2OS cells are deficient in inhibition of cell division–even in crowded 
culture–possibly due to overexpression of the c-myc gene that causes uncon-
trollable expression of various genes, including genes involved in cell prolifera-
tion.  
In Ref. I and II, U2OS cells were transfected with HPV genomes that were 
excised from bacterial vectors, religated, and concentrated. In Ref. III and IV, 
the method used to produce HPV genomes was changed, and minicircles of 
HPV plasmids were yielded using a previously established protocol (Kay et al., 
2010). In brief, HPV genomes were inserted into a pMC.BESPX vector and 
transformed into E. coli strain ZYCY10P3S2T. The culture was grown until 
optimal density, after which an equal volume of induction mix was added. Sub-
sequent inoculation for 5 h at 32°C allowed the bacteria to excise the bacterial 
backbone and religate the HPV genome. Plasmid DNA was extracted and gel 
purified to separate circular viral genomes from bacterial DNA. 
Although U2OS cells are not the native host of HPV, transfecting the cells 
with HPV genomes allowed us to monitor transient viral DNA amplificational 
replication, and subsequent single-cell subcloning allowed us to monitor the 
stable maintenance of viral genomes. The third phase (vegetative phase) of the 
HPV life cycle can be monitored in cells that can be induced towards differenti-
ation. Usually, in moderately differentiated cultures (such as U2OS cells), the 
vegetative phase of HPV infection cannot be induced. Interestingly, by cultur-
ing U2OS cells under dense culture conditions without splitting but with regular 
feeding, the unfavorable conditions do not trigger apoptosis. Instead, cell prolif-
eration is slowed down, and the cell cycle is presumably stalled in G2 phase. 
These conditions turned out to be ideal for HPV to re-initiate genome replica-
tion multiple times, as the second amplification replication phase, which is 
characteristic of the vegetative phase of infection, was observed. It should be 
noted that viral structural proteins are not expressed in U2OS cells, and viral 
particles are not produced. However, the lack of infective viral particles pro-
vides additional laboratory safety while handling the cells. 
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5. RESULTS AND DISCUSSION 
5.1 HPV replication proteins initiate replication from  
integrated HR-HPV replication origin and activate  
DNA damage response pathways (Ref. I)  
The coexistence of a replicating viral episome and integrated HPV sequences 
containing the potential replication origin is a quite usual phenomenon in 
HPV16-positive cancer cells. Additionally, other HPV types like HPV18, 
HPV31, HPV33, HPV52b, and HPV58, which are often found integrated into 
host chromosomes, also have a short period of time when episomal and inte-
grated HPV genomes coexist in the same cell. Integration of the functional HPV 
origin within the host cell chromosome is a serious threat to genomic stability. 
Under laboratory conditions, it has been demonstrated that episome-derived 
HPV replication proteins initiate replication from the integrated HPV origin, 
and the replication complex moves into the flanking cellular sequences up to 
12.6 kbp in both directions from the HPV origin (Kadaja et al., 2007). Because 
papillomaviruses do not follow a once-per-cell cycle replication mode (Hoff-
mann et al., 2006; Ravnan et al., 1992), multiple unscheduled replication 
initiations from the integrated HPV origin may occur, resulting in rearrange-
ments like deletions, duplications or even cross-chromosomal translocations of 
cellular DNA sequences by host cell repair/recombination machinery. 
To investigate the possibility of cross-chromosomal translocation of an inte-
grated HPV locus in vitro, we transfected SiHa cells with HPV16 or HPV18 
genomes and performed single-cell subcloning. Herein, HPV genomes (instead 
of E1 and E2 expression vectors) were used to demonstrate that more physio-
logical concentrations of replication proteins trigger DNA replication from the 
integrated HPV locus. Restriction analysis of total DNA from the subclones 
demonstrated de novo integration of newly synthesized replication products 
(Fig. 8E; Ref. I). Two HPV16-transfected subclones with new restriction pat-
terns were identified: they represented the integration of either transfected 
HPV16 plasmid into the host chromosome or the excision and re-integration of 
the integrated HPV16 sequences (Fig. 8E, lanes 7-12; Ref. I). More importantly, 
a new HPV16-specific restriction pattern was observed in one subclone trans-
fected with the HPV18 genome, indicating the re-location of integrated HPV16 
sequences (Fig. 8E, lanes 16-18; Ref. I). Parallel Southern blot analysis with an 
HPV18-specific probe revealed that, similarly to HPV16, a newly synthesized 
replication product from episomal HPV18 genome is also probably integrated 
into the host chromosome (8F, lanes 4-6; Ref. I). FISH analysis of subcloned 
SiHa cells transfected with HPV18 E1 and E2 expression plasmids revealed a 
new integration site of integrated HPV16 with the entire q-arm of chromosome 
13 (Fig. 7B; Ref. I), giving more evidence that episome-derived replication 
proteins induce genomic instability via replication initiation from the integrated 
HPV origin.  
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The process of how HPV integration is carried out is not well understood, 
but host cell DNA damage response pathways clearly play an important role in 
this event. Upregulation of the histone γH2AX is a hallmark of DNA double-
strand breaks in eukaryotic cells. Co-transfection of HPV18 E1 and E2 proteins 
into HeLa cells considerably elevates the formation of the phosphorylated form 
of γH2AX, indicating to the activation of a cellular response to the DNA DSBs 
generated by replication from the integrated HPV origin (Figure 6A, panel c, 
lane 1; Ref. I). Co-localization of ATRIP to the HPV replication foci indicates 
the presence of RPA-coated ssDNA (Fig. 5; Ref. I). However, the weak co-
localization of phosphorylated Chk1 (S317) to HPV replication centers (Fig. 5; 
Ref. I) might refer to the poor activation of the ATR pathway, which is not suf-
ficient to prevent the re-replication of integrated HPV sequences. This might be 
due to the limited targets available in HPV repair/recombination centers com-
pared to the complex cellular DNA replication-initiation mechanisms. However, 
the co-localization of ATM and Chk2 to integrated HPV DNA replication 
repair/recombination centers (Fig. 5; Ref. I) and the phosphorylation of Chk2 
kinase (Fig. 6B, panel b, lane 1; Ref. I) in HeLa cells transfected with HPV18 
E1 and E2 expression plasmids highlight the important role of the ATM path-
way in resolving DNA damage. We believe that since the ATR signaling path-
way is not fully functional, the ATM pathway is probably the pathway of choice 
for HPV DNA repair. Activation of the ATM pathway induces S or G2/M cell 
cycle arrest, which provides an environment to re-replicate viral genomes mul-
tiple times. This is most beneficial in the vegetative stage of the viral life cycle, 
where large numbers of viral genomes are needed.  
Depending on the phase of the cell cycle, the ATM pathway is divided 
between two principal repair mechanisms: homologous recombination (HR), 
which is activated in late S-phase or in G2-phase when sister chromatids are 
available, and non-homologous-end-joining (NHEJ), which does not need any 
homology and can repair dsDNA breaks at any phase of the cell cycle. The pri-
mary sensors to detect DSB in the HR pathway are in the MRN (Mre11-Nbs1-
Rad50) complex, and in case of NHEJ, the primary sensor is the Ku70/80 heter-
odimer. Co-immunostaining of HR or NHEJ complex proteins with the E1 pro-
tein, which represents the integrated HPV DNA replication centers (Fig. 2; Ref. I), 
revealed that all components of the MRN complex as well as the Ku70/80 
heterodimer co-localize within foci of the E1 protein (in HeLa cells transfected 
with HPV18 E1 and E2 expression plasmids) (Fig. 4; Ref. I). These data 
demonstrate that both repair mechanisms are recruited to the repair/recom-
bination centers of the integrated HPV locus to resolve HPV-derived DNA 
breaks. Although, HR is the primary DNA repair mechanism in late S and G2 
phase, we propose that the slow “error-free” HR pathway for repair of HPV-
derived DSBs is easily saturated and that DSBs are then repaired by the “error-
prone“ NHEJ pathway. Although NHEJ plays important role in maintaining 
genomic stability and preventing tumorigenesis, it is also responsible for the 
majority of cross-chromosomal translocations. De novo synthesized sequences 
can therefore be randomly integrated into the host genome and, depending on 
46 
the location, can cause genomic instability, which then can lead to uncontroll-
able cell growth and to the formation of cancer tissue.  
Mucosal HPVs classified into the low-risk group due to their lower onco-
genic activity have been considered harmless regarding progression to malig-
nancy. However, it has been demonstrated that the E1 and E2 replication pro-
teins originating from episomal low-risk HPV6b or HPV11 are capable of 
starting replication from an integrated high-risk HPV URR in HeLa and SiHa 
cells (Kadaja et al., 2007). The possibility that cells containing integrated HPV 
sequences could be the targets of de novo infection of another type of papillo-
mavirus (including LR-HPV) should not be underestimated. In such cases, epi-
somal and integrated HPV DNA co-exists in the same cell. Whether there is a 
benefit for the HPV type that re-infected the cell needs further clarification, as 
episomal forms of HPV have a tendency to be lost soon after integration.  
A “hit-and-run” mechanism can be used to describe the situation: although “the 
newcomer” will not complete its life cycle, the expression of replication pro-
teins and the damage done by amplifying the integrated HPV locus and its 
flanking cellular sequences remain. The possibility that low-risk HPVs 
indirectly cause genomic rearrangements needs to be further analyzed. There-
fore, it is necessary to study LR-HPVs in parallel with HR-HPVs to better un-
derstand differences between the groups, including in the viral life cycle, gene 
expression and DNA replication. 
 
 
5.2 Transient, stable and amplificational  
replication of the low-risk HPV11 genome can  
be monitored in U2OS cells (Ref. II, Ref. IV) 
Knowledge gained from studies with organotypic raft cultures has had a very 
large impact on understanding of how HPV infection runs its course. The down-
side of organotypic culture is largely technical, as the cultivation method is 
time-consuming and strict growth conditions make the results prone to varia-
bility. Furthermore, organotypic cultures are not suitable for screening thou-
sands of chemical compounds to find anti-viral drugs that target important vital 
HPV functions. It has been our goal for several years to find an alternative sim-
plified cell culture system that stably replicates HPV genomes. Previous studies 
with monolayer epithelial cells (C33A, 293, HaCaT, HeLa, and SiHa) have 
been suitable for monitoring DNA replication of plasmid containing HPV repli-
cation origin in the presence of the E1 and E2 replication proteins expressed 
from expression plasmids but in general have lacked the power to monitor the 
replication of HPV genomes in the presence of native expression levels of repli-
cation proteins. After transfection of U2OS cells with various types of HPV E1 
and E2 expression vectors together with origin-containing plasmids, we realized 
that this system is highly effective in initiating HPV DNA replication and made 
it possible to monitor viral DNA replication at much lower concentrations of 
replication proteins than in previously used cell lines (HeLa, SiHa, etc.). Most 
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importantly, the replication of HPV genomes can be easily followed in this cell 
system.  
Regardless of the fact that bone cells are not the native hosts of HPV, the 
effective replication of various alpha (HPV6b, 11, 16, and 18) and beta (HPV5 
and 8) HPV genomes can be easily monitored in U2OS cells without the addi-
tion of expression plasmids for the E1 and E2 proteins. The levels of viral repli-
cation proteins expressed from viral promoters are sufficient to initiate DNA 
replication from the viral origin of replication. Transient DNA replication of the 
above-mentioned HPV types was followed 4 days with continuous growth of 
the replication signal (Fig. 1A, B, C, and D; Ref. II). There were differences 
regarding replication signal intensity, but in general, all HPVs tested herein 
efficiently replicated their genomes in U2OS cells. The robustness of U2OS 
cells is the greatest advantage over other cell culture systems, as previously 
used cell lines could not support the genome replication of various HPV types, 
especially low-risk α-HPVs and β-HPVs. Additionally, compared to organo-
typic cell culture models, the U2OS transfection system is simple, safe and easy 
to use, and it can be adapted for automated industrial use to screen HPV repli-
cation inhibitors.  
Stable maintenance of extrachromosomal LR-HPV molecules has always 
been a limitation of in vitro cultures. Stable cell lines carrying extrachromoso-
mal molecules of high-risk HPV16 or HPV33 have long been used under labor-
atory conditions; however, no cell lines carrying LR-HPVs have been 
described. Single-cell subcloning of HPV18-positive (and HPV16-positive) 
U2OS cells has been very successful in creating stable clones that have been 
used to further describe the transcripts of HPV18, to characterize the oligomeric 
forms of the HPV18 genome and also to perform initial viral DNA replication 
inhibitor studies. The stability of HR-HPV-positive clones likely arises from the 
switch from initial amplificational replication of the HPV genome to a stable 
maintenance phase. To analyze the stability of HPV11 genome copy number 
over time, the possible growth advantage of untransfected cells was excluded by 
using selective growth conditions. For that, plasmids containing a selection 
marker and the HPV11wt genome were co-transfected into U2OS cells. Subse-
quent cultivation in Geneticin-containing media eliminated untransfected cells 
and enriched the culture with Geneticin-resistant cells. Post selection, the cells 
were regularly passaged and the density of the culture was kept at 70–80%. 
Total DNA was extracted every 2 days, and the samples were analyzed by 
Southern blotting. In this process, the downside of the adapted U2OS transfec-
tion system was revealed: the replication signal of the HPV11wt genome gradu-
ally decreased in a time-dependent manner from days 10 to 21 post transfection 
(Fig. 1B, lanes 1-6; Ref. IV), indicating to the instability of genome copy num-
ber maintenance. LR-HPV genome stability was also an issue when developing 
single-cell subclones. Although selection of HPV6b and HPV11-positive clones 
with different genome copy number was generated (Fig 2C; Ref. II), the overall 
effectiveness of isolating HPV11- and HPV6b-positive clones from cells carry-
ing the selection marker alone was 29% and 15%, respectively, compared to the 
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45% of isolation efficiency obtained for HR-HPV-positive subclones. Addition-
ally, in some of the LR-HPV-positive clones, the loss of extrachromosomal 
HPV molecules was observed after multiple passaging (Fig 2D, clone 6b #41; 
Ref. II). Few of the clones stably maintained LR-HPV genomes at low concen-
trations (Fig 2D, clone 6b #11; Ref. II), and in one case, a possible integration 
event of the HPV11 genome and the loss of episomal molecules was observed 
(Fig 2D, clone 11 #3.13; Ref. II). The integration of LR-HPV is very uncom-
mon and has not described before. The loss of episomal LR-HPV molecules 
may reflect to the lower capability of the E2 protein to effectively bind to HPV 
molecules and to mitotic chromosomes during cell division compared to  
HR-HPVs. As a consequence, we believe that the instability of LR-HPV clones 
is a natural feature of this HPV type, while HR-HPVs are considered to have 
more stability in both copy number maintenance and in generating persistent 
infection in humans.  
In terminally differentiated keratinocytes, papillomaviruses switch to the 
vegetative phase of the viral life cycle, in which DNA copy number is quickly 
amplified. Depending on the culture conditions, different approaches can be 
used to mimic the differentiation program of keratinocytes in vitro: (i) by 
growing keratinocytes in organotypic raft cultures where cells are grown at an 
air-liquid surface and where daughter cells can migrate only vertically or (ii) by 
suspending cells in semi-solid media (Flores et al., 1999, 2000, Frattini et al., 
1996, 1997). However, by cultivating moderately differentiated U2OS cells in 
dense culture conditions, the second rapid DNA amplification of HPV genomes 
can be observed (Fig. 3; Ref. II; Fig. 1B; Ref. IV). For closer investigation, 
equal numbers of cells per plate from a selection of HPV18 (18 #1.13), HPV16 
(16 #2.5), HPV11 (11 #74), HPV6b (6b#82) and HPV5 (5#23) cell clones were 
seeded and maintained without passaging but with regular feeding for up to 12 
days (Fig. 3; Ref. II). A similar study was also carried out with Geneticin-
resistant U2OS cell pools initially co-transfected with HPV11 genomes and a 
selection marker plasmid (Fig. 1B, lanes 7-11; Ref. IV). In both studies, total 
DNA was extracted at 2-day intervals during the growth period. The samples 
were analyzed by Southern blotting, and replication signals were measured 
using a PhosphorImager and ImageQuant software (Ref. II) or with qPCR anal-
ysis (Ref. IV). With these experiments, the different behaviors of the HPV types 
were again revealed: DNA replication intensity increased most with the HPV18 
#1.13 cell clone (approximately 10-fold), a general increase in genome copy 
number was observed for the HPV16 and HPV11 cell clones, and minimal 
increase in copy numbers were detected for the HPV6b and HPV5 clones (Fig 
3C and G; Ref. II). In general, similar results were obtained with HPV11 cell 
pools that, in addition to HPV11-positive cells, also contained cells harboring 
only the selection marker. However, only the stable maintenance of the HPV11 
genome could be monitored in dense culture conditions (Fig. 1B, lanes 7-11; 
Ref. IV), and the overall effect of changing the culture conditions on HPV11 
genome replication was not observed (Fig. 1B, compare lanes 1-6 with 7-11; 
Ref. IV). The reason that dense culture conditions trigger HPV genome ampli-
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fication may be the result of cell cycle arrest in G2 phase. Since HPVs do not 
follow once-per-cell-cycle replication mode (Hoffmann et al., 2006) and HPV 
replication activity has also been described in G2 phase, it is logical to assume 
that cell cycle arrest creates the perfect environment for HPV to amplify the 
viral genome. However, subsequent analysis of HPV5 and HPV8 clones did not 
exhibit an amplificational replication mode during a 12-day cultivation period 
in confluent culture conditions (Sankovski et al., 2014). The incapability of  
β-HPVs to amplify their genomes in confluent conditions may reflect to the lack 
of certain critical factors for the amplification of HPV5 and HPV8 genomes in 
U2OS cells.  
  
 
5.3 Papillomavirus DNA replication is regulated through  
the activity of the E8^E2 fusion protein (Ref. IV) 
Papillomavirus DNA replication is regulated through transcription, translation, 
post translational modifications, and nuclear localization of the E1 and E2 repli-
cation proteins, as well as through the expression of the E8^E2 fusion protein, 
which is a negative regulator of viral DNA replication. In order to test the effect 
of the HPV11 E8 ORF-containing fusion protein on HPV11 DNA replication, a 
mutant HPV11E8- genome was generated via a single nucleotide substitution of 
ATG to ACG at the E8 start codon at nt 1242 in the HPV11 genome. The muta-
tion of the E8 ATG start codon in the HPV11 genome disrupts the translation of 
the E8^E2 fusion protein. Transfection of the mutated HPV11E8- genome into 
U2OS cells considerably increased transient DNA replication compared to the 
HPV11wt genome (Fig. 1A, compare lanes 4-6 with 1-3; Ref. IV). The same 
effect was found with other HPVs tested in our lab, although the intensity of the 
replication signal was quite variable and depended on the HPV type. For the 
HPV18E8- genome, a 10-fold increase in replication signal was detected (Toots 
et al., 2014), and for the HPV5E8- genome, even higher levels of replication 
signal (up to 100-fold) have been described (Sankovski et al., 2014). The ability 
to increase the replication signal through a simple single nucleotide substitution 
has been beneficial in studies with HPV18 in which the replication signal was 
enhanced in order to detect the mode of replication through a transient DNA 
replication assay by describing replication intermediates using 2D electrophore-
sis (Orav et al., 2015) and to detect the oligomerization of HPV genomes (Orav 
et al., 2013). 
A slight decrease in HPV11E8- genome replication signal was detected in a 
stability assay in which Geneticin-resistant U2OS cell pools, initially trans-
fected with the HPV11E8- genome and a selection marker plasmid, were culti-
vated in actively dividing culture for 21 days (Fig. 1B, lanes 12-17; Ref. IV).  
A similar loss in genome copy number was also observed for the HPV11wt 
genome (Fig. 1B, lanes 1-6; Ref. IV). Parallel analysis of HPV11wt and E8- cell 
pools in dense culture conditions where equal number of cells were seeded and 
maintained without passaging but with regular feeding for 11 days showed that, 
50 
while HPV11wt genome copy number was stably maintained under these con-
ditions (Fig. 1B, lanes 7-11; Ref. IV), HPV11E8- genome DNA replication was 
amplified, with an increase in replication signal of 5- to 6-fold (Fig. 1B, lanes 
18-22; Ref. IV).  
In HPV11 transcript analysis using an E8-specific forward primer, we 
detected two differently spliced E8 ORF-containing transcripts. Sequencing 
analysis revealed that (i) E8^E1 is composed of the E8 ORF, the E1 3´ end and 
the intact E2 ORF, and (ii) E8^E2 contains the E8 ORF and the 3´ end of the E2 
ORF. To evaluate the role of both E8 ORF-containing proteins in the regulation 
of HPV11 DNA replication, we constructed expression plasmids for E8^E1 and 
E8^E2 (for details, see the Mat/Meth in Ref. IV). Co-transfection of increasing 
amounts of these expression vectors with the HPV11E8- genome indicated that 
the expression of the E8^E1 protein did not affect the replication of the HPV11 
genome (Fig. 1C, lanes 2-5; Ref. IV). It seems like E8E1 is not needed for the 
regulation of DNA replication and may be important in other parts of the viral 
life cycle. However, a strong reduction of HPV11E8- genome replication was 
observed after the E8^E2 expression vector was introduced into U2OS cells 
(Fig. 1C, lanes 7-9; Ref. IV).  
 
 
5.4 Recombination-dependent oligomerization of  
HPV genomes in vitro and in vivo (Ref. III) 
Episomal HPV molecules containing several copies of covalently closed circu-
lar HPV genomes (further referred to as oligomers) have been described as early 
as the 1980s (Boshart et al., 1984). The factors driving the formation of oligo-
meric HPV molecules and why these molecules are formed are not well under-
stood, as the virus functions through its monomeric form, and ultimately only 
unit-size genomes are packed into viral particles. We can only speculate that the 
oligomeric forms provide an advantage when viral DNA is segregated between 
daughter cells or when the viral load is quickly amplified during the vegetative 
phase of infection. Oligomeric forms can result from active sigma-type rolling 
circle replication that generates long, linear head-to-tail dsDNA forms that are 
then recognized and circularized by host cell DNA damage repair (DDR) path-
ways. For example, a σ-type replication mode is used by phage λ to produce the 
tandem repeats required for λ DNA packaging (Weller and Sawitzke, 2014b). 
Oligomeric forms can also be the product of homologous recombination-
dependent replication. Unlike rolling circle replication, which needs one tem-
plate to produce linear multimeric DNA forms, homologous recombination 
combines two separate molecules into one.  
In studies of HPV DNA replication in U2OS cells, we noticed that in addi-
tion to monomeric HPV molecules, higher forms of HPV molecules were also 
present (Ref. II). After closer investigation, it became clear that those forms 
were head-to-tail concatemers of HPV genomes (Fig. 2; Ref. III). To investigate 
whether HR-dependent or rolling circle replication is used to produce oligo-
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meric HPV molecules, two distinguishable HPV18 molecules (HPV18wt and 
HPV18E) or HPV11 mutant genomes (HPV11E1- and HPV11E2-) were trans-
fected into U2OS cells. Co-transfection of HPV18wt and the truncated form of 
HPV18E (plasmid without the late ORFs) produced oligomers containing both 
forms of HPV18 genomes (Fig. 5b, lanes 5-8; Ref. III). Co-transfection of repli-
cation-incompetent HPV11E1- and HPV11E2- also produced oligomers that 
contained both genome variants (Fig. 6, lanes 13-16; Ref. III). The production 
of heterogenic molecules is characteristic only to homologous recombination-
dependent replication. Oligomeric forms of HPV DNA are also produced in 
other eukaryotic cell lines, such as HeLa, SiHa and C33 A cells (Fig. 7; Ref. III). 
It seems that the oligomerization of HPV molecules is formed in all cell lines 
that also support HPV genome replication.  
In collaboration with the Women’s Clinic of the University of Tartu Hospi-
tal, we analyzed cervical brush or colposcopy probes collected from women 
with persistent infection of HPV16 or HPV18. Via restriction analysis of total 
DNA with subsequent 1D or 2D electrophoresis and the detection of HPV-spe-
cific signal by Southern blotting, we identified 3 samples containing both 
oligomeric and monomeric forms of HPV molecules (Fig. 8; Ref. III). Taken 
together, the fact that oligomeric forms of HPV molecules can be produced in 
vitro and the presence of such forms in vivo indicates that oligomerization of 
HPV genomes seems to be a naturally occurring event. Large viruses such as 
vaccinia virus encode resolvase (Garcia et al., 2000) and herpes simplex virus 
encodes alkaline nuclease (Martinez et al., 1996) to cleave long concatemeric 
replication intermediates back to unit-sized viral genomes. For small viruses 
such as HPV, the factors that assist in this process are not known. Therefore, the 
cleavage of HPV oligomers is probably mediated by the host cell. The processes 
through which HPV manipulates or adapts host factors to resolve oligomeric 
molecules remain to be understood. 
 
 
5.5 Mapping of HPV11 transcripts in U2OS cells (Ref. IV) 
mRNA splicing is an important modification mechanism among viruses with 
small compact genomes, as one sequence often encodes various proteins with 
different functionality. HPV11 has 3 splicing donor sites and 3 acceptor sites 
within its early region that in combination form a set of proteins essential for 
successful progression through the viral life cycle. Knowledge about HPV11 
transcripts has been gained from studies with human clinical samples (Chow et 
al., 1987a; Nasseri et al., 1987a; Rotenberg et al., 1989a; Smotkin et al., 1989) 
and from studies with the transiently transfected human squamous carcinoma 
cell line SCC-4 (Renaud and Cowsert, 1996). Although the transient replication 
of various HPV types as well as the expression of functional E1 and E2 proteins 
from native promoters within HPV genomes has been described in U2OS cells 
(Fig. 1; Ref. II), little was known about the overall gene expression of HPV in 
these cells. Recently, transcription maps of HPV5 and HPV18 were created 
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(Sankovski et al., 2014; Toots et al., 2014), and a part of this thesis focused on 
describing the transcripts of HPV11 expressed from the HPV11 genome in 
transfected U2OS cells. A thorough characterization of HPV11 transcripts 
expressed in U2OS cells and subsequent comparison with transcripts character-
ized by others would add more reliability to the results obtained with the U2OS 
cells and would further show the suitability of these cells for studies with 
human papillomavirus. 
After introducing HPV11wt and E8- genomes into U2OS cells by transfec-
tion, polyA+ mRNA was extracted, and 3´ RACE, 5´ RACE or RT-PCR analy-
sis with HPV11-specific primers was performed (Ref. IV). As we have demon-
strated that different culture conditions trigger stable or amplificational replica-
tion of HPV genomes, the same two culture conditions were introduced during 
HPV11 transcript analysis to gain insight into the changes that occur at the tran-
scriptional level. For that, U2OS cells were transfected with the HPV11wt 
genome together with a Geneticin-resistant plasmid, and the cells were culti-
vated under selective media and maintained under subconfluent and confluent 
conditions.  
For 3´ RACE analysis, polyadenylation cleavage sites (CS) were mapped to 
nt 4384, where early-region transcripts are cleaved, and to nt 7458, which is 
necessary for the cleavage of late-region mRNAs (Fig. 3; Ref. IV). Both CSs 
have also been described in previous studies with HPV11 transcripts (Chow et 
al., 1987b; Nasseri et al., 1987b). Interestingly, use of the early CS does not 
change significantly over time in U2OS cells (Fig. 3A; Ref. IV), indicating that 
viral early proteins are needed throughout the entire period that was under anal-
ysis. At the same time, increased use of the late CS was found at later time 
points and under dense culture conditions (Fig. 3B; Ref. IV), which may indi-
cate that viral structural proteins are needed for the production of viral particles 
characteristic of the vegetative phase of the viral life cycle. However, 5´ RACE 
analysis with specific late-region HPV11 primers was used for the detection of 
mRNA products encoding viral structural proteins composed of mixed mRNA 
products that exhibited irregular splicing patterns (data not shown). We believe 
that late mRNAs are unstable and are easily degraded in U2OS cells, which is 
why late structural proteins are not synthesized. The same phenomenon was 
also found following transcript analysis of HPV18 and HPV5 in U2OS cells: 
although the use of late CS was clearly upregulated, no intact mRNAs encoding 
late viral proteins were detected (Sankovski et al., 2014; Toots et al., 2014). 
The HPV11 transcriptional start sites (TSS) were mapped through 5´ RACE 
analysis with different HPV11-specific reverse primers located in exon regions 
previously characterized by others. With this method, the TSSs were clustered 
into 5 promoter regions: P90, P264, P674-714, P1092, and P1372. The P1092 
and P1372 TSSs are quite rarely used and have not been extensively defined as 
promoter regions in studies with HPV11. However, a transcriptional start site at 
nt 1374 has been suggested in studies with SCC-4 cells with autonomously rep-
licating HPV11 genomes, and depending on its 3´ end, the E2, E4, E5a, and E5b 
proteins are encoded (Renaud and Cowsert, 1996). A potential transcriptional 
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start site of P1092 identified herein could be used for the expression of the 
E8^E2 fusion protein. A short exon within the E1 ORF that fuses with the C-
terminal end of the E2 ORF has been previously described in HPV11 by Chow 
et al. in 1987, and transcriptional start sites other than the ones in front of the E1 
gene have also been suggested (Chow et al., 1987a). Similar use of a promoter 
has previously been reported in studies with HPV1 (Palermo-Dilts et al., 1990) 
and HPV16 (Milligan et al., 2007), but a lack of detection mechanisms or addi-
tional structural information has hindered the subsequent characterization of this 
region. For BPV1, thorough analysis to describe the promoter region within the 
E1 ORF was carried out, and in combination with multiple experiments such as 
primer extension, S1 nuclease mapping, and RNase protection analysis, the 
promoter region (P3) was mapped to the first half of the E1 gene at the N-ter-
minal end (Choe et al., 1989). It has also been reported that the P3 promoter 
region is used for the transcription of mRNAs that express the strong transcrip-
tional and replicational repressor E8^E2, described earlier by Lambert et al. 
(Lambert et al., 1987). 
The promoter regions located in the E6 and E7 ORFs, P90, P264, P674-714 
are divided as early and late promoters that are utilized in a differentiation-spe-
cific manner. In undifferentiated basal keratinocytes, the E2-dependent pro-
moter P90 is used to transcribe the early transcripts needed for host cell trans-
formation and viral DNA replication. In the progression of the viral life cycle 
and after host cell differentiation, the E2-independent late promoter P674-714 is 
activated. The switch from early to late promoter is not strict, as the differentia-
tion of host cells increased the abundance of both the P90 and P674-714 tran-
scripts, and only isolated suprabasal cells almost exclusively contained tran-
scripts starting from the late promoter (DiLorenzo and Steinberg, 1995). In 
transfected U2OS cells, all of the previously described promoters can be 
detected with a clear prevalence of the P90 promoter over the P264 and P674-
714 promoter regions (Fig. 4A; Ref. IV), indicating to the early stages of the 
viral life cycle. The activity of the P90 promoter region varies at different time 
points: the signal is stronger in samples cultured for 10 days compared to those 
cultured for 4 days (Fig. 4A and C, compare lane 2 with 1; Ref. IV). Under 
dense culture conditions where amplificational DNA replication has been 
described and presumably higher levels of replication proteins are needed, use 
of the P90 promoter region is enhanced (Fig. 4A and C, lane 3; Ref. IV). Use of 
the late promoter region also becomes more evident at later time points and in 
dense culture conditions (Fig. 4A; Ref. IV). However, increased P90 promoter 
signal at the same probes indicate that although the viral life cycle may have 
progressed further and late promoter activity was upregulated, it has not reached 
the phase where early promoter activity is minimized, as has been described in 
suprabasal cells by DiLorenzo and Steinberg (DiLorenzo and Steinberg, 1995). 
In transcript analysis of HPV11 from condylomata acuminata, mRNAs were 
predominantly initiated from the late promoter region P674-714, which may 
indicate that the infection reached the end of the viral life cycle, at which point 
use of the P90 promoter region is downregulated (Chow et al., 1987a).  
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Regulation of the P264 promoter has been a controversial topic. Some stud-
ies have shown that transcripts started from this promoter are more abundant in 
suprabasal cells (Stoler et al., 1989), whereas others have detected higher abun-
dance in the two to three lowest epidermal layers (Iftner et al., 1992). In vitro 
studies with cells cultured in low-calcium media (conditions that minimize dif-
ferentiation and stratification) showed that the abundance of P264 transcripts 
was lower or equal to the transcripts started from the early P90 promoter 
(DiLorenzo and Steinberg, 1995). In raft cultures where cells were induced 
towards differentiation with a high calcium concentration, the abundance of 
P264 transcripts remained unchanged, while P90 and P674-714 transcript levels 
both increased. Treatment of laryngeal papilloma cell culture with increasing 
concentrations of retinoic acid, which also induce cell differentiation, led to a 
concentration-dependent decrease in the levels of P264 transcripts, but the 
abundance of P90 transcripts was less affected (DiLorenzo and Steinberg, 
1995). These results show that LR-HPV promoters are differentially regulated, 
suggesting that independent regulation of the levels of E6, E7 and other viral 
proteins is important for efficient progression through the viral life cycle. In 
transfected U2OS cells, the P264 promoter region is rarely used compared to 
the early promoter P90. However, a slight increase in the use of the P264 pro-
moter was observed at later time points and under dense culture conditions (Fig. 
4A; Ref. IV). At the same time, the P90 and P674-714 promoters were also 
upregulated. 
Splicing of papillomavirus mRNAs is the key event in producing proteins 
with various purposes from the same sequence. The splicing donor and acceptor 
sites were characterized in HPV11-transfected U2OS cells by sequencing 
cDNAs obtained by 5´ RACE or by RT-PCR methods using polyA+ mRNA 
extracts as a template. With these methods and with various HPV11-specific 
primers, we were able to detect three splice donor sites at nt 847, nt 1272, and nt 
1459, and three acceptor sites at nt 2622, nt 3325, and nt 3377, which are 
identical to those previously found in human condylomas, in laryngeal 
papillomas and in transfected SCC-4 culture. The data demonstrate the presence 
of transcripts containing splice junctions representing all possible combinations 
of detected splice donor and acceptor sites: 847/2622, 847/3325, 1272/2622, 
1272/3325, 1272/3377, 1459/2622, 1459/3325, and 1459/3377 (Fig. 4D, E, F, 
and Fig. 5). Additionally, using 5´ RACE with HPV11-specific primers from 
the latter exon enabled the identification of TSSs together with the splice sites 
(Fig 4D, and E; Ref. IV). Data regarding the transcripts detected during 
transient HPV11 replication are summarized in Figure 8, with the transcripts 
that were previously detected by others being designated by the numbers on the 
right. With this set of mRNAs in transfected U2OS cells, there is the potential 
to encode all the major early-region proteins described to date. Therefore, the 
transcript map created for HPV11 supports the use of this cell system as a 




Figure 8. HPV11 transcription map obtained from transiently transfected U2OS 
cells. The HPV11 ORFs, LCR, promoters (P90, P264, P674-714, P1092, and P1372) 
and polyadenylation CSs (Cs 4384 and Cs 7485) are shown at the top of the figure. All 
HPV11 transcripts from transiently transfected U2OS cells (indicated with letters from 
A-Q, shown at left) are presented, showing the exons (solid boxes), introns (lines) and 
splicing donor and acceptor sites (nt numbers in HPV11 genome). The inferred 5′ ends 
of the RT-PCR products (N-Q) are indicated with dashed boxes. The coding potential is 
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described to the right of each transcript, and references are provided when similar tran-
scripts were found by others, namely, Chiang et al., 1991 (1), Chow et al., 1987 (2), and 
Renaud et al., 1996 (3). 
 
 
5.6 Role of the E6/E7 ORF in the production of  
functionally active E1 protein (Ref. IV) 
Preliminary R-loop studies with HPV11 transcripts derived from condyloma 
acuminata suggested that the E1 protein is translated from monocistronic 
mRNA that starts from the late promoter region P674-714 (Chow et al., 1987a). 
The early promoter region P90, which produces polycistronic mRNA, was 
believed to be used for the production of oncoproteins E6 and E7 (Chow et al., 
1987a). Although knowledge about the viral factors (E1 and E2) needed for 
BPV1 genome replication has been available since the beginning of the 1990s 
(Ustav and Stenlund, 1991), in vitro HPV replication studies using E1 expres-
sion vectors took quite a long time to get going due to poor expression levels of 
E1, until Remm et al. described using an HPV18 model that biologically active 
E1 protein levels can be produced by introducing the E6/E7 ORFs in front of 
the E1 gene in E1 expression plasmids (Remm et al., 1999). This structural 
organization mimics transcription from the early promoter region in front of the 
E6 ORF, which produces polycistronic mRNA, with the E1 ORF being the third 
coding region. The effective expression of the E1 protein from the designed E1 
plasmid shows the crucial regulatory role of the E6/E7 region. However, little is 
known about the cis elements responsible for E1 protein expression. Since 
HPVs are very conserved in genomic structure, the E6/E7 ORFs were also 
introduced into HPV6b, HPV11, and HPV16 E1 plasmids, and the effective 
expression of the E1 protein in transfected HeLa cells was observed (Kadaja et 
al., 2007). Efficient replication from a homologous URR-containing plasmid as 
well as replication initiation from the integrated HPV18 sequence could be 
detected in all of the HPV types under investigation (Kadaja et al., 2007).  
To further evaluate the role of the E6/E7 region in HPV11 E1 protein 
expression, we designed an E1 plasmid that lacks the E6/E7 region (Leader-) 
and compared the results with an HPV11 E1 plasmid that contains the E6/E7 
region (Leader+), as designed by Kadaja et al. (Kadaja et al., 2007). Similarly 
to Remm et al., the HPV11 E1 protein expression plasmids containing the E6 
and E7 ORF showed higher E1 protein levels (Fig. 6A, Leader+; Ref. IV) and 
supported URR plasmid replication more effectively (Fig. 6C, lanes 1-6; Ref. 
IV) than the E1 expression plasmid lacking the E6/E7 region (Fig. 6A and C, 
Leader-; Ref. IV) (Remm et al., 1999). Interestingly, while Kadaja et al. intro-
duced high concentrations (2.5 and 10 µg) of Leader+ plasmids into HeLa cells 
to obtain detectable E1 protein levels, U2OS cells require far less plasmid (up to 
1 µg) to obtain even higher levels of E1 protein expression than those observed 
in HeLa cells. This again shows the suitability of the U2OS system, as was pre-
viously described in studies with various HPV genomes (Fig. 1; Ref. II).  
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In high-risk HPV subtypes such as HPV16, HPV18, and HPV31, the E1 
protein is translated from spliced polycistronic mRNA, which carries partial 
sequences of the E6 ORF (generating E6* protein) (Milligan et al., 2007; Ozbun 
and Meyers, 1998; Wang et al., 2011). We believe that splicing from the E6 
ORF may contribute to the effective expression of the E1 protein. In LR-HPVs, 
such an intron has not been described. However, cloning of an intron in front of 
the E1 coding region in an HPV11 E1 expression plasmid and the effective 
splicing of translated mRNA (Fig. 7, Int1; Ref. IV) increased E1 protein expres-
sion and the URR plasmid replication signal to levels comparable to those pro-
duced with the Leader+ plasmid (Fig. 6A, compare lanes 7-9 with 1-3, and Fig. 6C, 
compare lanes 13-18 with 1-6; Ref. IV). Expression of E1 protein was even 
more intense from a plasmid containing two introns in front of the E1 coding 
sequence than from the Leader+ or Intron1 plasmids (Fig. 6A, Intron2; Ref. IV). 
However, the toxicity of high E1 protein levels also seemed to be a burden for 
host cells, as the replication signal of the URR plasmid dropped in the presence 
of higher levels of E1 protein (Fig. 6C, lanes 25-26; Ref. IV). Interestingly, 
75% of mRNAs translated from the plasmid with the double intron were spliced 
from the second intron, leaving the first intron intact, whereas 25% were spliced 
from both introns, and no mRNAs spliced only from the first intron were 
detected (Fig 7B, Int2, signal e; Ref. IV). In addition to the detected splicing 
event of the E1 intron plasmids, the Leader+ plasmid that contains the E6/E7 
region and the viral native promoters P264 and P674-714 showed a weak signal 
at approximately 750 bp, and sequence analysis of this HPV11-specific mRNA 
revealed that native promoters were used to transcribe E1 mRNAs, although at 
low levels (Fig. 7, L+, signal b; Ref. IV). 
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6. CONCLUSION 
1) The observation of new integration sites of HPV16 sequences with flank-
ing cellular sequences in SiHa cells transfected with the E1 and E2 
expression vectors indicate that replication initiation from integrated 
HPV origins may lead to host cell genomic rearrangements. As a result of 
the re-replication of integrated HPV16 sequences, the co-localization of 
homologous recombination and non-homologous end joining effector 
molecules (MRE complex, Ku70/80, ATM, ATRIP, and Chk2) to HPV 
repair/recombination loci indicate to the formation of double-stranded 
breaks. The produced replication intermediates were detected as aberrant 
DNA molecules and were subjected to cellular repair/recombination 
pathways. Most of the ds breaks were repaired properly, but in some 
cases, DNA rearrangements were generated. Our work suggests that the 
de novo integration of HPV16 loci in SiHa cells is mediated by cellular 
DNA damage response pathways. This provides additional evidence in 
support of the hypothesis that amplification of integrated HPV loci 
together with flanking cellular sequences in pre-cancerous lesions (LSIL 
and HSIL) could occur if episomal-derived replication proteins are pre-
sent. 
2) The oligomerization of HPV genomes observed in U2OS cells is con-
sistent with findings from clinical samples. Analysis of HPV16- or 
HPV18-positive cervical brush or colposcopy probes confirmed that 
oligomerization of HPV genomes is a naturally occurring event. Oligo-
merization of HPV genomes could be generated through a recombi-
nation-dependent replication mode or through homologous recombina-
tion. In the first case, DNA replication is not terminated when the repli-
cation complex reaches the replication initiation site but continues for 
several rounds of replication on circular molecules. This type of replica-
tion can produce only homologous oligomeric DNAs. In the second case, 
homologous recombination combines two molecules together and can 
produce heterogeneous oligomers. In U2OS cells, both recombination 
variants were detected. 
3) The transient replication of mucosal low-risk (HPV6b, HPV11) and high-
risk (HPV16, HPV18) α-HPVs as well as the replication of cutaneous  
β-HPVs (HPV5, HPV8) can be easily monitored in U2OS cells. Stable 
maintenance of HPV6 and HPV11 subclones as well as HPV11 cell pools 
is complicated, as genome copy number has a tendency to continuously 
decrease over time. The amplificational replication of HPV6 and HPV11 
subclones in confluent U2OS culture can be detected. In the case of the 
HPV11 cell pool, confluent culture conditions rather helped stably main-
tain HPV11 genome copy number than triggered DNA amplification. At 
the same time, clones of HR-HPV types were stably maintained under 
normal culture conditions (70–80% confluency), whereas dense culture 
conditions triggered active amplification replication. 
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4) The identification of HPV11 transcripts with transcriptional start sites, 
polyadenylation cleavage sites, and splice sites in U2OS cells and the 
similarity of the transcription pattern to previous findings in clinical sam-
ples and in keratinocyte cell lines provides additional support for the use 
of U2OS cell-based assays in HPV research.  
5) Expression of the HPV11 E1 protein from polycistronic mRNA produces 
more stable and functionally active E1 protein than E1 protein translated 
from monocistronic mRNA. Although HPV11 does not contain an intron 
within the E6 region such as the HR-HPVs, E1 expression levels and the 
replication of URR-containing plasmid were positively affected when an 
intron was introduced into the monocistronic E1 expression vector. The 
viral promoters within the E6/E7 region are also active as mRNAs with 
TSSs at the P264 or P674-714 promoter regions are transcribed from 
polycistronic E1 expression vector. However, the contribution of this 
activity to the expression of functionally active E1 protein is unknown 























SUMMARY IN ESTONIAN 
Viiruse ja peremeesraku interaktsioonid  
inimese papilloomiviiruse elutsüklis 
Papilloomiviirused on väga laialdase levikuga ning pea kõik inimesed naka-
tuvad mingil eluetapil selle viirusega. Üldiselt kulgeb HPV infektsioon üsna 
kergelt, põhjustades nahal või limaskestadel healoomulisi vohandeid, soolatüü-
kaid (β-HPV) või kondüloome (α-HPV). Kliiniliselt oluliseks peetakse aga 
papilloomiviirusi seetõttu, et selle viiruse infektsiooniga on seotud enamik emaka-
kaela vähi juhtumitest. Arvatakse, et emakakaela vähi tekke üks olulisemaid 
etappe on raku nakatumine kõrgesse riskigruppi kuuluva papilloomiviiruse sub-
tüübiga. Kui soolatüükaid ja kondüloome põhjustavad madala riskiga inimese 
papilloomiviiruste subtüüpide infektsioon aja möödudes kaob, siis emakakaela 
vähki põhjustavate viiruste infektsioon muutub kergesti pikaajaliseks. Sellisesse 
faasi jõudnud nakkuse ravivõimalused on aga väga piiratud, mistõttu on HPV 
infektsiooni varajane avastamine eduka ravi seisukohalt ülioluline.  
Papilloomiviiruse infektsioon kulgeb tavaliselt läbi ekstrakromosomaalse 
rõngasmolekuli ning viiruse elutsükli edukaks lõpetamiseks ei ole integreeru-
mine peremeesraku pärilikku materjali (DNA) tingimata vajalik. Vähirakkude 
geneetilisel uurimisel on aga muuhulgas HPV nakkuse tuvastamisele avastatud 
ka asjaolu, et väga paljudel juhtudel on papilloomiviiruse genoomi osad integ-
reerunud peremeesraku kromosoomidesse, muutes HPV DNA üheks osaks 
peremeesraku pärilikust materjalist. HPV genoomi osaline integratsioon rikub 
ära aga mitmete viiruse jaoks oluliste valkude ekspressiooni (s.h. DNA replikat-
siooniks ja virioni moodustamiseks vajalike valkude sünteesi). Seega peetakse 
integreerumist viiruse seisukohalt tupikteeks. Peremeesraku seisukohalt aga 
peetakse pahaloomuliseks kasvajaks arenenud rakkude DNAs tuvastatud suuri 
ja tagasipöördumatuid muutusi just viiruse integratsiooni tagajärjeks. Viiruse 
integratsioon võib toimuda mistahes kromosoomi piirkonda, ka nendesse piir-
kondadesse, mis on peremeesraku kasvu ja jagunemise kontrolli seisukohalt 
väga olulised.  
Kuna nakatunud rakk sisaldab keskmiselt 100 ekstrakromosomaalset viiruse 
genoomi koopiat ning massilist genoomide integratsiooni tavaliselt ei toimu, 
tekib olukord, kus ühes rakus eksisteerib kaks erinevat viiruse DNA vormi: üks, 
puudulike geenidega integreerunud vorm ja teine, täiesti funktsionaalne ekstra-
kromosomaalne vorm. Kuigi integreerunud viiruse DNAlt ei saa enam ekspres-
seerida DNA paljundamiseks vajalikke replikatsioonivalke, siis ekstrakromoso-
maalselt molekulilt replikatsioonivalkude sünteesiks mingeid takistusi ei ole. 
Selline olukord on aga peremeesraku genoomse stabiilsuse seisukohalt väga 
ohtlik, kuna integreerunud HPV järjestused sisaldavad viiruse DNA paljunda-
miseks vajalikku alguskohta (replikatsiooni origin-i), mis ei ole rakuliste regu-
latsiooni faktoritega kontrollitav. Sellelt järjestuselt alustatud DNA replikat-
sioon, põhjustab nii integreerunud HPV DNA kui ka sellega külgnevate 
peremeesraku genoomi osade kontrollimatut paljundamist (amplifikatsiooni). 
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Olenevalt integratsiooni kohast, võivad integreerunud HPV järjestusega külg-
nevad alad sisaldada onkogeene või muid raku kasvu ja jagunemisega seotud 
regulatoorseid geene, mille amplifikatsioon võib põhjustada raku genoomset 
ebastabiilsust ning kontrollimatut kasvu ja jagunemist. Lisaks võib põhjustada 
HPV-dele omane litsentseerimata DNA re-replikatsioon replikatsiooni komp-
lekside takerdumisi, mis viib ebatüüpiliste DNA replikatsiooni produktide 
kuhjumiseni raku tuumas. Rakulise DNA reparatsiooni radade võtmemolekulide 
lokalisatsioon HPV DNA replikatsiooni tsentritesse viitab rakuliste mehhanis-
mide olulisele rollile tekkinud kaheahelaliste DNA katkete parandamisel. Kui 
enamik kaheahelalisi DNA katkeid parandatakse õigesti, siis antud väitekirjas 
kirjeldatud viiruse integratsiooni koha translokatsioon uude kromosoomi piir-
konda viitab ebaõnnestunud katsele parandada DNA amplifikatsiooni tagajärjel 
tekkinud DNA produkte. Seega, integreerunud HPV järjestuste amplifikatsioon 
ja peremeesraku vastusena aktiveeritud DNA reparatsiooni mehhanismid võivad 
viia peremeesraku genoomse ebastabiilsuseni ja vähkkasvaja tekkeni. 
Inimese papilloomiviiruste uurimine nende looduslikes peremeesrakkudes 
on üsna keerukas just keratinotsüütide keeruka elutsükli tõttu, mis on aluseks 
nahkkoe kihistunud struktuuri moodustumisel. Kui diferentseerumata basaalsed 
keratinotsüüdid on pidevas jagunemises ja vastutavad basaalrakkude populat-
siooni uuenemise eest, siis diferentsieerumisradadele suunatud rakud läbivad 
kontrollitud rakusurmaga lõppeva elutsükli. Mitmes eri diferentseerumisastmes 
olevate keratinotsüütide populatsioon tekitab nahkkoe kihistunud struktuuri, 
mille peamiseks ülesandeks on tagada tugev (ja läbimatu) barjäär sise- ja välis-
keskkonna vahel. Kuna viirus nakatab diferentseerumata basaalseid kerati-
notsüüte ja pakib oma viiruspartiklid alles terminaalselt diferentseerunud rakku-
des, on papilloomiviirused kohanenud kõikide peremeesraku eluetappidega. 
Lühidalt, papilloomiviirus nakatab basaalseid keratinotsüüte mikrovigastuste 
kaudu ning peale viiruse geneetilise materjali jõudmist raku tuuma, toimub 
esmalt aktiivne viirusgenoomi paljundamine. Peale optimaalse genoomi koopia-
arvu saavutamist, lülitub viirus ümber stabiilsele genoomi säilimisele ning jääb 
ootama peremeesraku diferentseerumist. Sel ajal toimub HPV- ja peremeesraku 
geneetilise materjali sünkroonne paljundamine ning viiruse genoomide peaaegu 
ühtlane jaotumine tütarrakkude vahel. Terminaalselt diferentseerunud rakkudes 
toimub taaskord aktiivne genoomi paljundamine (amplifikatsioon) ning viimase 
etapina viiruspartiklite moodustumine. Laboritingimustes on keratinotsüütide 
kasvatamine ja elutsükli mimikeerimine tehniliselt keerukas, ajakulukas ja kül-
laltki kallis. Lisaks ei ole otstarbekas niigi kapriisset rakukultuuri kasutada laia-
mahuliseks kemikaalide skriinimiseks, et leida HPV elutsüklit pärssivaid kom-
ponente. Meie laboris välja töötatud sääreluu kasvaja rakuliiinil U2OS põhinev 
HPV uurimismudel osutus edukaks mitmete HPV subtüüpide (β-HPV5,  
β-HPV8, α-HPV6b, α-HPV11, α-HPV16, α-HPV18) transientse, stabiilse kui ka 
amplifikatsioonilise DNA replikatsiooni jälgimisel. Kuna U2OS rakud ei ole 
looduslikud papilloomiviiruse peremeesrakud, pidasime vajalikuks kaardistada 
viiruse geenide avaldumist, et tõsta U2OS rakusüsteemi usaldusväärsust HPV 
uuringutes. Antud töös kirjeldati HPV11 geenide ekspressiooni, kuid sarnane 
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analüüs on läbi viidud ka HPV5 ning HPV18 subtüübiga. Kõiki saadud tule-
musi on võrreldud viiruse loomulikest peremeesrakkudest, keratinotsüütidest, 
saadud tulemustega ning nende sarnasuse tõttu oleme arvamusel, et U2OS 
süsteem on sobiv keskkond papilloomiviiruste uurimiseks ning oma lihtsuse ja 
odavuse poolest ideaalne ka esialgsete ravimi kandidaatide skriinimiseks. 
Lisaks tuvastati U2OS süsteemis 1n HPV molekulide sünteesi kõrval ka 
suuremaid, 2n ja rohkem, järjestikku paigutunud HPV genoomi koopiatega 
rõngasmolekule (oligomeerid). Sarnaseid vaheprodukte on täheldatud nii 
varasemates kui ka antud töö raames kogutud HPV-positiivsetest kliinilistest 
koeproovidest. HPV-spetsiifiliste oligomeeride tekke täpsemal uurimisel tekkis 
hüpotees, et nende moodustumisel võib olla oma roll rakulise rekombinatsioo-
nilise DNA replikatsiooni laadil. Oligomeersed HPV molekulid võivad osutuda 
kasulikeks, et tagada kiire HPV genoomi koopia arvu tõus vegetatiivses viiruse 
elutsükli faasis kui ka viiruse genoomi jagunemisel kahe tütarraku vahel. Kuna 
viiruspartiklisse pakitakse vaid üks HPV genoom, pole täpselt teada, milliseid 
mehhanisme kasutatakse oligomeersete DNA vormide konverteerimisel tagasi 
1n HPV genoomideks. 
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